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ABSTRACT 
The pathogenesis of inflammatory rheumatic diseases, including 
rheumatoid arthritis (RA) and spondyloarthropathies (SpAs) such as reactive 
arthritis (ReA), is incompletely understood. The inflammatory functions of 
the innate immune system in these diseases were studied in the present 
thesis. 
Reactive arthritis (ReA) is a sterile joint inflammation, which may 
follow a distal infection caused by Gram-negative bacteria that have lipopoly-
saccharide (LPS) in their outer membrane. The LPS receptor, CD14/Toll-like 
receptor 4 (TLR4)/MD-2, is mainly expressed on innate immune cells and 
mediates, for example, the production of the essential pro-inflammatory 
cytokine tumour necrosis factor (TNF).  
We observed that peripheral blood monocytes of subjects with 
previous ReA showed high secretion of TNF, which was evident in response to 
adherent in vitro conditions (mimicking the vascular endothelium made 
adherent by inflammatory signals) and non-specific stimulation (referring to 
TNF production capacity). Also, rapid induction of TNF production, which 
depended on adherence, was high in these subjects. Thus, enhanced TNF 
production capacity of adhering monocytes may be involved in the 
development of ReA. One possible mechanism is aberrant signalling through 
CD11b/CD18, the major molecule mediating monocyte adhesion to the 
endothelium and cell culture well surfaces.  
Peripheral blood neutrophils of patients with previous ReA showed 
significantly high CD11b levels in response to physiological and concentrated 
LPS levels or adherence. Thus, circulating neutrophils that encounter 
bacterial material or adhere seem highly responsive, which may be associated 
with the pathogenesis of ReA. The increased CD11b levels may result from 
abnormal CD14/TLR4/MD-2 - or CD11b/CD18 -mediated signal transduction.  
HLA-B27 predisposes to SpAs by an unknown mechanism. Our 
findings suggest that previous ReA and HLA-B27 positivity are additive 
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factors to bring about the elevated TNF production and CD11b expression. 
HLA-B27 may be involved by its functions as an antigen-presenting MHC class 
I molecule, as an antigen or by its tendency to misfold in endoplasmic 
reticulum, which could affect the transport or synthesis of other proteins. 
The promoter polymorphisms TNF -308G/A and CD14 -159C/T have 
been associated with transcriptional activity of the corresponding genes and 
risk of inflammatory conditions. Among our patients, all females that 
developed chronic SpA had the -159T allele and none had the -308A allele. This 
may reflect some interrelated effects of hormonal and inflammatory signals. 
Rheumatoid arthritis (RA) is a systemic inflammatory disease 
characterised by synovitis, progressive joint destruction and disability. Its 
activity should respond to the treatment rapidly in order to maintain the 
patient’s work ability. Our results suggest that TLR4 +896AG (causing the 
Asp299Gly change in the TLR4 molecule) could be an advantageous marker 
when choosing the treatment strategy: patients with the G allele required a 
combination of disease-modifying antirheumatic drugs. Perhaps Asp299Gly 
alters the response to LPS or endogenous TLR4 ligands (e.g. those present in 
the inflamed joints). 
VEGF (vascular endothelial growth factor) promotes both the 
increased vascular permeability characteristic of the inflamed sites and 
angiogenesis that takes place early in the rheumatoid synovium. We found 
that LPS induced and IFN-α inhibited VEGF production by peripheral blood 
mononuclear cells, suggesting a role for LPS-induced VEGF in the 
pathogenesis of systemic inflammatory disorders, such as RA, and the ability 
of IFN-α to prevent undue angiogenesis in the inflammatory response. 
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INTRODUCTION 
Inflammation is the protective reaction of vascularised tissues against 
invading microbes and physical and chemical dangers. It is triggered by the 
activation of innate immunity, which discriminates rapidly and 
nonspecifically between self and non-self, and prevents the spreading of the 
damaging factor by mechanical, chemical and microbiological barriers. The 
effector cells of innate immunity are phagocytes: macrophages that patrol in 
tissues, and circulating monocytes and neutrophils, the former continuously 
migrating to become macrophages and the latter being quickly recruited to 
the inflamed sites. 
A classical innate receptor that mediates phagocyte activation is 
CD14/Toll-like receptor (TLR) 4/MD-2, which binds lipopolysaccharide (LPS) 
of Gram-negative bacteria and possibly some endogenous ligands. Binding 
triggers intracellular signalling leading e.g. to the production of the crucial 
pro-inflammatory cytokine tumour necrosis factor (TNF). This and other 
inflammatory mediators make the local vascular endothelium express 
molecules that bind to CD11b/CD18 and other adhesion molecules on 
circulating immune cells. The subsequent binding of phagocytes and their 
recruitment and activation in the tissue compartment are among the most 
important functions of innate immunity. 
The other part of the immune system, i.e. the T and B lymphocyte-
based adaptive immunity, recognises specific foreign epitopes and raises a 
response against the invader expressing those epitopes. This effective system, 
however, becomes activated slower than innate immunity because, first, there 
are originally only a few T or B cells specific for a given antigen. Second, the 
adaptive effector cells, which are initially activated in secondary lymphoid 
tissues, must find their targets in the body thereafter. Furthermore, in order 
to become activated, B cells generally need help from already activated T cells. 
Hence, only if the mechanisms of innate immunity are evaded or over-
whelmed by the invader, is there time for adaptive immunity to be launched.  
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To provide the host with optimal protection, innate and adaptive 
immunity have evolved co-operating and complementary ways of action. They 
interact by cell-cell communication (e.g. antigenic peptides are presented with 
MHC class I and II molecules and recognised by T cells), humoral 
communication (mostly cytokines and chemokines) and by triggering the 
same effective amplifying systems (e.g. the complement system). Because 
innate immunity initiates adaptive immunity, failures of the innate system 
can have profound effects on the nature of the whole response.  
The pathogenesis of inflammatory rheumatic diseases, including 
rheumatoid arthritis (RA) and spondyloarthropathies (SpAs) such as reactive 
arthritis (ReA) is incompletely understood, but increasing evidence suggests 
that innate immune factors play a role. ReA is a sterile complication of an 
extra-articular infection, which is most commonly caused by Gram-negative 
bacteria in the gastrointestinal or urogenital tract. The strong clinical overlap 
of ReA and other SpAs suggests that bacterial infections may be involved in 
SpAs in general. HLA-B27, an MHC class I molecule, strongly predisposes to 
SpAs by an unknown mechanism. 
Rheumatoid arthritis is a chronic systemic inflammatory disease, in 
which many immune cells are involved, but the synovitis is predominated by 
macrophages and pro-inflammatory cytokines. In addition to HLA-DR1 alleles 
(MHC class II), which are known to predispose to RA, there is evidence of both 
microbes and gene-environment interactions in its pathogenesis.  
In this study, we examined the crucial features of innate immunity; 
the production of TNF and the expression of the activation marker CD11b in 
patients with previous ReA. We also studied the diagnostic and prognostic 
value of TNF and CD14 polymorphisms in arthritis. In early RA, markers are 
needed that reliably predict the outcome of alternative treatments for each 
individual, and here we tested the usefulness of TLR4 +896A/G that is 
associated with responsiveness to LPS. We also evaluated the effect of LPS 
and the endogenous immunoregulatory factor IFN-α on the angiogenic 
vascular endothelial growth factor (VEGF) production that occurs e.g. in the 
rheumatic joint.  
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REVIEW OF THE LITERATURE 
INNATE IMMUNITY 
PRINCIPLES 
The body distinguishes between self and harmful non-self by a wide 
array of approaches that can be divided into two fundamentally different 
strategies, innate and adaptive immunity (Chaplin 2003). Innate immunity 
appeared before the evolutionary split of the plant and animal kingdom, 
whereas adaptive immunity is only present in vertebrates and cartilaginous 
fish (Dempsey et al. 2003). The key differences between innate and adaptive 
immunity are listed in Table 1.  
The innate immune system comprises all the ready-to-use defence 
mechanisms, the components of which are encoded in the germ line: 
mechanical barriers (epithelial cell layers, tight cell-cell contacts), secreted 
mucus layer (lining the respiratory, gastrointestinal and genitourinary tracts) 
and cilia sweeping away the mucus, and soluble proteins and bioactive small 
Table 1. The diverse properties of innate and adaptive immunity. 
 
Property Innate immunity Adaptive immunity 
Main cell types Neutrophils, monocytes, 
macrophages 
T and B lymphocytes 
Receptors Fixed in the genome Assembled from gene 
segments 
Distribution Non-clonal expression 
All cells of a class identical 
Clonal expansion 
All cells of a class distinct 
Recognition Conserved molecular patterns 
(lipopolysaccharide, lipoteichoic 
acids, 
mannans, glycans) 
Detailed molecular 
structures 
Self-nonself 
discrimination 
Selected over evolutionary time Selected in individual 
somatic cells 
MHC restriction * No Yes 
Action time Immediate Delayed 
Memory ** No Yes 
 
* The antigen fragments must be presented combined with MHC (major histocompatibility 
complex) molecules on antigen-presenting cells. ** The response is started more quickly and 
powerfully on the subsequent encounters than on the first encounter with a given antigen. 
Modified from Janeway and Medzhitov 2002.  
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molecules (such as defensins) constantly present in biological fluids. All these 
mechanisms prevent the invasion of pathogens (Chaplin 2003) (Table 2). More 
usually, however, the concept of innate immunity is confined to the innate 
elements that sense the presence of a pathogen and respond to it - cells, 
receptors, the complement system and acute phase proteins. The 
characteristic response triggered by pathogen recognition and/or tissue 
damage is called inflammation, within which innate immunity uses various 
cytokines and adhesion molecules to communicate with the environment and 
to regulate the process (Parkin and Cohen 2001). 
During their life cycles, pathogens inevitably produce structural 
motifs, termed pathogen-associated molecular patterns (PAMPs), which are 
conserved in related microbial species but not present in the host. As the host 
has straightforward instructions for encountering PAMPs in the germ line 
(Dempsey et al. 2003) and expresses the innate recognition molecules broadly, 
the innate immune system is induced rapidly presenting the first line of 
defence (Chaplin 2003). In fact, adaptive immunity is only activated if the 
Table 2. Innate mechanisms in which recognition of pathogen structures is not 
involved. 
 
Mechanism Example  
Mechanical barrier Tight epithelium and keratin layer of the skin 
Mechanical removal Airway cilia 
Coughing 
Mucus on the mucosal membranes 
Washing effect of tears and urine 
Peristalsis in the gut 
Chemical attack Acidity of the stomach 
Fatty acids of the skin 
Lysozyme in saliva, tears and breast milk (degrades the 
peptidoglycan of bacterial cell walls) 
Antimicrobial peptides in the intestine 
Pancreatic degrading enzymes 
Detergent effect of bilic acids 
Prevention of 
colonisation  
Normal flora in the mouth, colon and urogenital tract 
Lack of specific receptors for bacterial adhesion  
Relatively low humidity of the skin 
Deprivation of 
nutrients 
Proteins sequestering iron (transferrin in the blood and tissues, 
lactoferrin in breast milk) 
 
Modified from Tramont and Hoover 1995, Janeway et al. 2005a. 
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innate mechanisms are bypassed, evaded or overwhelmed by pathogens 
(Janeway et al. 2005a). 
COMPONENTS 
Cells 
The main cells of the innate immune system are phagocytes, i.e. 
neutrophils, monocytes and macrophages. Other innate immune cells 
comprise basophils, mast cells and eosinophils that contribute to the response 
by releasing mediators, and natural killer (NK) cells, and dendritic cells that 
are very potent in presenting antigens to adaptive immune cells (Delves and 
Roitt 2000).  
Monocytes and macrophages  
Tissue macrophages are the first effector cells encountered by 
microbes that have managed to cross epithelial barriers (Janeway et al. 2005a, 
b). Macrophages are abundant in many tissues and their numbers further 
increase in inflammation, wounding and malignancy (Hume 2006). The source 
of macrophages are monocytes that continuously leave the circulation e.g. by 
interacting with the adhesion molecule ICAM-2 (Janeway et al. 2005b) and 
breast and kidney -expressed chemokine (BRAK; Kurth et al. 2001) on the 
resting vascular endothelium. 
In general, human monocytes express CD11b, CD11c and CD14, lack B, 
T, NK and dendritic cell markers, and have a bean-shaped nucleus. The 
monocyte pool is however heterogeneous, giving rise to different 
macrophages, such as peritoneal macrophages, Kupffer cells in the liver, 
alveolar macrophages in the lungs, microglia in the brain and osteoclasts in 
the bones (Geissmann et al. 2003). The use of different adhesion molecules and 
chemokine receptors by different monocyte subpopulations (Ancuta et al. 
2003), and monocyte differentiation capacity seem complex and are not 
entirely understood yet (Hume 2006). For instance, a monocyte subpopulation 
that is only minor in healthy individuals exhibits strong expression of CD16 
(receptor for the Fc portion of IgG), has enhanced capacity to produce pro-
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inflammatory cytokines like tumour necrosis factor (TNF) and interleukin 1 
(IL-1) and consequently, is recruited to inflammatory sites (Ancuta et al. 2003) 
and expanded in inflammatory conditions. However, the expression of CD16 is 
increased on monocytes by the anti-inflammatory cytokines transforming 
growth factor- (TGF-) and IL-10 (Kawanaka et al. 2002).  
The differentiation into macrophages requires macrophage-colony 
stimulating factor (M-CSF), the receptor of which is a marker of the monocyte-
macrophage lineage (Hume 2006). Upon reaching the macrophage stage, a cell 
achieves a more prominent phagocytic capacity along with receptors that 
sense activating signals (Duffield 2003). The nature of these signals directs the 
type of activation. First, IFN- and microbial material (e.g. lipopoly-
saccharide) induce the development of “classically” activated macrophages, 
which are very effective in the inflammatory response and killing of 
intracellular pathogens. Second, when exposed to IL-4 or glucocorticoids, 
“alternatively” activated macrophages arise that produce anti-inflammatory 
compounds (such as IL-10) and components for extracellular matrix synthesis 
and tissue repair. Finally, ligation of macrophage Fc receptors by IgG 
immune complexes leads to “type II activation” of macrophages, which 
promotes adaptive TH2 responses (Mosser 2003).  
Tissue macrophages have an important role not only in the 
antimicrobial response but also in the clearance of apoptotic senescent cells. 
Macrophages respond by phagocytosis to various “eat me” signals, including 
increased oxidation and altered distribution of plasma membrane lipids (e.g. 
phosphatidylserine exposed on the outer leaflet) (Savill et al. 2002).  
Dendritic cells (DCs) form a critical link between innate and adaptive 
immunity. They reside in tissues and continuously sample their environment 
by macropinocytosis. Pathogen-derived peptides and mediators induce DC 
maturation, whereby the stability of MHC II - peptide -complex is increased, 
for example, and DCs migrate to local lymph nodes to present antigenic 
peptides to naïve T cells (Dempsey et al. 2003). The markers of DCs and 
macrophages (such as the M-CSF receptor) are almost convergent, raising a 
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question if DCs represent a separate lineage or belong to the continuum of the 
mononuclear phagocyte system (Hume 2006). 
Neutrophils 
Neutrophils, i.e. polymorphonuclear leukocytes (PMNs), are not 
present in healthy tissues, but they are the first cells to accumulate in 
inflammatory foci. This rapid accumulation is partly due to the abundance of 
neutrophils in the circulation (representing approximately 70% of peripheral 
blood leukocytes in humans; Dempsey et al. 2003), and their stiffness that 
retains them in narrow capillaries readily adjacent to any inflammatory 
signals appearing (Witko-Sarsat et al. 2000). Also, macrophages of the damaged 
tissues produce G-CSF and GM-CSF that promote the supply of myeloid 
precursors from the bone marrow (Parkin and Cohen 2001). Furthermore, IL-8 
and the bacterial formylated Met-Leu-Phe peptide are chemotactic especially 
for neutrophils (Janeway et al. 2005b).  
The morphology of neutrophils is characterised by cytoplasmic 
granules containing toxic components that are mobilised intra- and 
extracellularly upon phagocytosis. This degranulation makes neutrophils the 
most rapid and prominent cells to phagocytose, and only a few microbes are 
able to evade killing inside them (Allen 2003). The potential of the granule 
contents to damage healthy host tissues is limited as neutrophils have the 
shortest life span among leukocytes (Dempsey et al. 2003, Kobayashi et al. 
2003). As a whole, neutrophils are crucial in the first-line defence against 
bacteria, fungi and protozoa (Faurschou and Borregaard 2003). 
Pattern recognition receptors (PRRs)  
The innate immune system recognises pathogens by PRRs that are 
expressed on the cell surface or in intracellular compartments or secreted into 
the blood and tissue fluids (Table 3). The principal PRR functions include 
opsonisation, activation of complement, blood clotting cascades, phagocytosis 
and pro-inflammatory signalling pathways, and induction of apoptosis 
(Janeway and Medzhitov 2002). The targets of PRRs are primarily molecules 
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that are essential for the survival or pathogenicity of the microbes and as 
such, not subject to antigenic variability. The innate strategy also includes 
that PRRs are typically expressed by cells that are the first to encounter 
pathogens invading the body (e.g. surface epithelia and macrophages) 
(Medzhitov and Janeway 1997). 
 
Table 3. Examples of pattern recognition receptors (PRRs). 
 
 Non-self ligand Self ligand Ref. 
Receptor on macrophage surface   
CD14 LPS, PGN LBP, PGRP, apoptotic cells, LDL, HSP, 
fibronectin 
A 
TLR (selected) LPS, PGN, LTA, 
unmethylated CpG, 
flagellin, lipoprotein, 
dsRNA, 
lipoarabinomannan 
HSP-60, PGRP, fibrinogen A 
Mannose receptor Terminal mannose, 
fucose, or GlcNAc  
Mannose on L-selectin and lysosomal 
hydrolases, sulphated saccharides on 
lutropin and TSH 
A 
Scavenger 
receptors A I/II 
Polyanionic ligands: 
dsRNA, 
lipid A of LPS, LTA 
Polyanionic ligands: modified LDL, 
apoptotic thymocytes 
A, B 
MARCO Bacterial cell walls, LPS, 
environmental particles 
Modified LDL A 
CD11b/CD18 
(CR3) 
 glucan in zymosan Promiscuous, e.g. ICAM-1 and  
-2, clotting factors, senescent platelets 
A 
 glucan receptor  glucan in zymosan and  
other yeast-derived 
particles 
Some T cells  
(independent of sugar groups) 
A 
CD1 Mycobacterial glycolipids Gal ceramide A 
 
Acute phase proteins secreted from the liver 
 
CRP and SAP Phosphorylcholine on 
bacteria 
C1q  B 
 MBL   Terminal mannose C2 and C4 via MASPs B 
 
Cytoplasmic receptors 
NOD1 and NOD2 Peptides derived from 
PGN 
Unknown C 
 
Ref., reference; LPS, lipopolysaccharide; LBP, LPS binding protein; PGN, peptidoglycan; 
PGRP, PGN recognition protein; LDL, low density lipoprotein; HSP, heat shock protein; LTA, 
lipoteichoic acid; GlcNAc, N-acetylglucosamin; TSH, thyroid stimulatory hormone; MARCO, 
macrophage receptor with collagenous structure; CR, complement receptor; ICAM, 
intercellular adhesion molecule; Gal, galactose; CRP, C reactive protein; SAP, serum amyloid 
protein; MBL, mannan binding lectin; MASP, MBL-associated serine protease; NOD, 
nucleotide binding oligomerisation domain. References: A, Gordon 2002; B, Janeway and 
Medzhitov 2002; C, Strober et al. 2006. 
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Pattern recognition is diverse: a single PRR usually recognises various 
target structures (Medzhitov and Janeway 1997), combinations of different 
PRRs engage complex ligands, and different cell types of innate immunity 
respond by distinct gene expression profiles. As the ligands also include self 
molecules on stressed, transformed, senescent or infected cells, or even 
normal self molecules, pattern recognition could be seen as a part of a wider 
homeostatic clearance system (Gordon 2002). 
LPS receptor complex (CD14/TLR4/MD-2) 
LPS is a complex glycolipid constituting the outer layer of the outer 
membrane of Gram-negative bacteria. Its structure was elucidated in the 
early 1970s (Luderitz et al. 1973). The three covalently linked parts of LPS are 
1) the innermost region, lipid A, 2) the core oligosaccharide, and 3) the 
outermost region, O side chain consisting of branched tetrasaccharides 
(Miyake 2004). 
The immune system is stimulated by LPS that is released from dying 
bacteria or processed by the host. LPS-binding protein (LBP) is a lipid 
transferase occurring in the serum. It binds to lipid A and catalyses the 
transfer of LPS from the bacterial membrane to the LPS receptor complex, 
which is mainly expressed on monocytes and macrophages (Miyake 2004). The 
three essential components of the LPS receptor complex (Figure 1) as known 
so far are CD14 (Wright et al. 1990), Toll-like receptor 4 (TLR4; Poltorak et al. 
1998) and MD-2 (Shimazu et al. 1999).  
CD14 is a glycoprotein that is either anchored to the plasma membrane 
via a glycosylphosphatidylinositol tail (mCD14) or circulates as a soluble 
molecule (sCD14) (Miyake 2004). The role of mCD14 is to bind LPS and present 
it to TLR4/MD-2 (Pålsson-McDermott and O’Neill 2004). sCD14 facilitates LPS 
clearance by delivering it to high-density lipoprotein (HDL) particles, within 
which LPS is neutralised and excreted from the liver (Miyake 2004). 
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Of the known components of the LPS receptor complex, only TLR4 has 
a membrane-spanning region and hence, signal transduction capacities 
(Pålsson-McDermott and O’Neill 2004). TLR4 is the human homologue of 
Drosophila Toll, which in turn was the first member of the Toll family of cell 
surface receptors discovered. Drosophila Toll is required in the embryonic 
formation of the body of the fly but also, depending on other proteins 
expressed, in an adult fly in antimicrobial responses (Janeway and Medzhitov 
2002). Human Toll-like receptors are directly linked to pro-inflammatory 
signalling (Miyake 2004) and may also be activated by self molecules that 
indicate tissue injury or stress (e.g. heat shock proteins and hyaluronate 
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Figure 1. The LPS receptor complex. LPS, lipopolysaccharide; TIR, Toll/interleukin-1 
receptor; TLR4, Toll-like receptor 4. Modified from Miller et al. 2005, Pålsson-McDermott 
and O’Neill 2004. 
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fragments). However, as bacterial products, foremost LPS, activate TLRs even 
in trace amounts, bacterial contamination as the reason for “endogenous” 
TLR activation results cannot be excluded (Tsan and Gao 2004). 
MD-2 is a secreted adapter protein. It mediates TLR4 aggregation, 
which is essential for the initiation of LPS signalling (Pålsson-McDermott and 
O’Neill 2004). Two independent signalling pathways are triggered at TLR4: an 
earlier one involving myeloid differentiation factor 88 (MyD88) which acts 
downstream of all TLRs and the IL-1 receptor, and a delayed MyD88-
independent one (Figure 2). The former pathway leads to the activation of 
MAP kinases and the transcription factor NF-B, and the latter to the 
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Figure 2. Simplified model of signalling from TLR-4. Negative regulators are not shown. 
IFN, interferon; IKK, B kinase; IRAK, interleukin-1 receptor -associated kinase; IRF, 
interferon response factor; ISRE, interferon-sensitive response element; JNK, c-Jun N-
terminal kinase; LPS, lipopolysaccharide; Mal, MyD88 adapter-like; MKK, mitogen-activated 
protein kinase kinase; MyD88, myeloid differentiation marker; NF-B, nuclear factor-B; RIP, 
receptor-interacting protein; TBK, TANK-biding kinase; TLR, Toll-like receptor; TRAF6, 
tumour necrosis factor receptor-associated protein; TRIF, TIR-containing adapter molecule; 
TRAM, TRIF-related adapter molecule. Modified from Pålsson-McDermott and O’Neill 2004.  
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activation of interferon regulatory factor 3 (IRF3) and NF-B (Miyake 2004, 
Pålsson-McDermott and O’Neill 2004).  
Intestinal epithelial cells also recognise LPS (from pathogens in food). 
In these cells, LPS is first internalised and then transported to the Golgi 
apparatus where TLR4 is located (Miyake 2004). 
Inducible components 
Unlike the resident cells and receptors, other innate elements are only 
synthesised, released or made functional when triggering signals appear. 
These elements usually act as mediators in the inflammatory response, and 
are rapidly degraded or otherwise inactivated to target the powerful response 
appropriately and to minimise the damage they might cause to the host 
(Parkin and Cohen 2001, Mitchell and Cotran 2003).  
Cytokines and chemokines 
Cytokines are the most prominent inducible elements of the immune 
system. They are primarily leukocyte-derived small molecular weight (8-80 
kD) messengers that bind to specific receptors on target cells and alter cell 
behaviour, typically activation, division, apoptosis and movement. They act 
either in an autocrine (on the producer cells), paracrine (on cells near-by) or 
endocrine fashion (via bloodstream). An immune insult induces the 
production of cytokines, which in turn directs the extent and type of the 
developing response. Cytokines can be divided into subgroups according to 
their major targets or functions, e.g. interleukins (ILs) mainly influence 
leukocytes and interferons (IFNs) interfere with viral replication (Parkin and 
Cohen 2001).  
Chemokines are small (8-12 kD) cytokines having a characteristic 
cysteine sequence, and were originally described as chemoattractants 
recruiting immune cells to the inflammatory site. More recently, some of 
them have also been shown to perform homeostatic or housekeeping functions 
(Borish and Steinke 2003) like BRAK mentioned above has (Kurth et al. 2001). 
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In most cases, contribution of several cytokines is required for optimal 
function. A given cytokine may even have opposite effects depending on the 
type of the target cells and the phase of the response. Most cytokines 
predominantly exhibit either pro- or anti-inflammatory effects (Borish and 
Steinke 2003). 
INFLAMMATORY RESPONSE 
Inflammation is the main host response to tissue injury, aimed at 
eliminating the triggering factor, e.g. an invading microbe, allergen, poison or 
mechanical trauma. The acute response to each of these different triggers is 
very similar, reflecting the innate non-specific nature of the early stages of 
inflammation and the same repertoire of the mediators used (Mitchell and 
Cotran 2003). Infection, i.e. inflammation caused by a microbe, can only occur 
if the epithelial barriers protecting the skin, respiratory, gastrointestinal and 
urogenital tract are colonised by the pathogen, or crossed by it via a wound, 
abrasion, sting, burn etc (Janeway et al. 2005a).  
Mediators 
More than a hundred compounds are known that target, regulate, 
modulate or complement each other in the inflammatory response (Table 4). 
Some of them have a broad spectrum of effects, others have only one point of 
action. 
The effects of the mediators are observed as the four classical clinical 
symptoms at the inflamed site: they cause heat and redness because they 
induce vasodilation leading to increased blood flow, they cause swelling 
because they promote the infiltration of blood leukocytes (by activating the 
vascular endothelium), fluid and proteins (by increasing vascular 
permeability), and they cause pain because some mediators stimulate pain 
nerve endings. The fifth symptom, dysfunction, depends on the tissue/organ 
and the overall process (Mitchell and Cotran 2003).  
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Upon microbial invasion, three plasma protein systems are quickly 
activated. The complement system recognises antigen-antibody complexes, 
cell wall polysaccharides of Gram-negative bacteria and yeasts, or non-self 
mannose patterns in proteins and carbohydrates, causing osmotic lysis of the 
microbe and generating additional mediators (Delves and Roitt 2000, Parkin 
and Cohen 2001). The kinin system (most importantly bradykinin) is activated 
by negatively charged surfaces such as on collagen, the basal membrane, or 
LPS (Mitchell and Cotran 2003). The local blood clot created by the activated 
coagulation system prevents the spreading of the microbe (Janeway et al. 
2005a).  
Table 4. Important inflammatory mediators classified by their major effects. 
 
Vasodilation 
Prostaglandins 
Nitric oxide (NO) 
Increased vascular permeability 
Vasoactive amines (histamine, serotonin) 
Complement components C5a and C3a 
Cysteinyl leukotrienes (LTC4, LTD4, LTE4) 
Tumour necrosis factor (TNF), interleukin 1 (IL-1) 
Bradykinin 
Platelet activating factor (PAF) 
Chemotaxis 
Complement component C5a 
Leukotriene B4 (LTB4) 
Bacterial products 
Chemokines (e.g. IL-8) 
Fever 
IL-1, IL-6, TNF 
Prostaglandins 
Pain 
Prostaglandins 
Bradykinin 
Tissue damage 
Degradative enzymes and oxygen metabolites of neutrophils and macrophages 
NO 
Regulation of leukocyte functions 
Cytokines, e.g. TNF, IL-1, IL-6, IL-12 
Interferons 
LTB4 
PAF 
Complement component C5a 
 
Modified from Mitchell and Cotran 2003. 
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Tissue macrophages respond rapidly to invading pathogens by 
producing large amounts of mediators. These guide the entry of circulating 
phagocytes, and activate them and tissue cells (Dempsey et al. 2003). Cell-
derived early mediators include lipid derivatives, chemokines and cytokines. 
Arachidonic acid from membrane phospholipids is used in the synthesis of 
eicosanoids, i.e. prostaglandins and leukotrienes, and phosphatidylcholine is 
used in the synthesis of platelet-activating factor (PAF) (Mitchell and Cotran 
2003). Important cytokines secreted by macrophages include TNF (tumour 
necrosis factor), IL-1, IL-6, IL-8 and IL-12 (Janeway et al. 2005b). TNF and IL-1 
have many effects in common and bring about the majority of the 
inflammatory features. Typically, the pro-inflammatory cytokines regulate 
target cell functions by inducing the activation of certain transcription 
factors, which include NF-B, AP-1 and the STAT family (Mitchell and Cotran 
2003). 
TNF  
In the mid-1970s, a protein with a selective antitumour effect was 
described and named tumour necrosis factor (Carswell et al. 1975) (although, 
in some cell types, TNF-induced killing is apoptotic rather than necrotic). 
TNF also revealed to contribute to severe wasting, cachexia, which often 
accompanies chronic infections and cancer. In particular, TNF is the main 
and early-induced mediator of the response against bacterial LPS (Fiers 1991). 
It can also be induced by other toxins, immune complexes, mechanical tissue 
damage and numerous other inflammatory signals (Mitchell and Cotran 2003). 
It is produced by monocytes and macrophages but also, after appropriate 
induction, by neutrophils, lymphocytes, NK cells, endothelial and mast cells 
(Borish and Steinke 2003).  
TNF in its native conformation is a trimer with a molecular mass of 52 
kDa. Of the two TNF receptors, TNF-RI is ubiquitous, while TNF-RII is more 
restricted to cells of hematopoietic origin and strongly expressed on T cells 
upon activation. The clefts between the three subunits of TNF can interact 
with the receptors cross-linking them, which initiates intracellular signal 
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transduction events (Fiers 1991). TNF enhances local inflammatory response 
by inducing the expression of adhesion molecules, cytokines, growth factors, 
eicosanoids and nitric oxide in endothelial cells, the metabolism of fibroblasts 
and functions of leukocytes, e.g. neutrophils (Mitchell and Cotran 2003). 
TNF is also able to act from a distance to coordinate the host response 
(Figure 3). For instance, its effects on the hypothalamus (mediated by 
prostaglandin E2) and fat and muscle cells elevate body temperature. Fever is 
generally beneficial to the host because it slows down the growth of most 
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Figure 3. The ways by which the cytokine TNF coordinates the body’s response to 
infection. IL-1 and IL-6 share these effects, except for the effect on dendritic cells. Adapted 
from Janeway et al. 2005b. 
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pathogens and intensifies adaptive responses. On the other hand, TNF-
promoted catabolism, fatigue and loss of appetite enhance the wasting effect. 
Furthermore, once a pathogen has managed to spread to the circulation, TNF 
production occurs systemically causing an explosive, deleterious response 
(Janeway et al. 2005b). 
Acute phase response 
The so-called acute phase response is launched within 48 hours of 
pathogen exposure. Acute phase proteins are defined as hepatocyte-derived 
plasma proteins whose concentration is increased or decreased by at least 
25% by the effect of the cytokines TNF, IL-1 and especially IL-6 (Gabay and 
Kushner 1999). CRP was the first acute phase protein discovered (Tillett and 
Francis 1930) and currently, elevated CRP level is the most widely used 
indicator of an ongoing inflammatory reaction. CRP recognises 
phosphocholine of bacterial and fungal cell wall lipopolysaccharides and 
when bound to these it is able to opsonise and activate the complement 
cascade. MBL is also increased in inflammation, and it activates complement 
by binding to microbial mannose residues and acts as an opsonin for 
monocytes (Janeway et al. 2005b).  
Recruitment of phagocytes 
Under normal conditions, circulating leukocytes travel in the fastest 
blood flow in the center of the vessel lumen. In the early stages of 
inflammation, physical changes and the appearance of adhesion molecules 
and chemokines on the vascular endothelium take place, guiding the 
phagocytes to attach to the vessel walls and be recruited to the inflamed sites. 
This is one of the most important functions of innate immunity (Janeway et 
al. 2005b). 
The migration of phagocytes (and other leukocytes) out of blood 
vessels, i.e. extravasation, occurs in four steps (Figure 4). The first step, 
tethering, is mainly guided by glycoconjugate-binding molecules, selectins. 
Most circulating leukocytes express L-selectin and glycoproteins such as P-
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selectin glycoprotein ligand-1 (PSGL-1) on the tips of their microvilli. L-
selectin recognises sulphated sialyl-LewisX (sLeX) -like sugars in glycoproteins 
or -lipids on the inflamed endothelium and in PSGL-1 on adherent leukocytes 
(Luster et al. 2005). 
On the endothelial side, P-selectin is unloaded from cytoplasmic 
granules to the cell surface within minutes of exposure to TNF, LTB4, C5a or 
histamine. TNF and LPS also trigger the transcription of the E-selectin gene. 
The interactions between selectins and their ligands are not strong enough to 
anchor phagocytes but instead, make phagocytes “roll” on the endothelium, 
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Figure 4. Extravasation of a neutrophil across the vascular endothelium in four steps. 
1) Rolling adhesion. Reversible binding of carbohydrate ligands on the leukocyte and 
selectins on the endothelium makes neutrophils roll on the endothelium. 2) Firm adhesion. 
Chemokines (such as IL-8) and rolling enable the neutrophil to form stronger interactions 
between integrins (CD11b/CD118, CD11a/CD18) and immunoglobulin-like ligands (ICAM-1) on 
the endothelium, and to arrest rolling. 3) Crossing the endothelium. Homophilic PECAM-1 
interactions and integrins are needed for crossing the endothelial barrier. Penetrating the 
basement membrane (diapedesis) requires degradative enzymes on the leukocyte surface. 4) 
Migration. The concentration gradient of chemokines guides the migration of neutrophils 
towards the pathogen in the tissue. Leukocyte enzymes degrade and modify extracellular 
matrix for the migrating neutrophil to move onwards. Modified from Janeway et al. 2005b. 
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continually making and breaking contacts. Inflammatory chemokines (such 
as IL-8) are trapped by endothelial proteoglycans to become bound by 
chemokine receptors on rolling phagocytes. Receptor-mediated intracellular 
signals are rapidly transmitted to cell surface integrins, resulting in a 
conformational change that enhances the ability to integrins to bind to their 
ligands (members of the immunoglobulin superfamily) on the endothelium. 
The involvement of integrins arrests rolling and launches the second step of 
extravasation, firm adhesion. The most relevant phagocyte integrins in the 
inflammatory migration are 2 integrins CD11b/CD18 (Mac-1, CR3) and 
CD11a/CD18 (LFA-1). They bind to ICAM-2 and ICAM-1, which is induced on 
the endothelium by TNF (Janeway et al. 2005b).  
In the third step phagocytes cross the endothelium paracellularly, i.e. 
by squeezing between endothelial cells, which is facilitated by the increased 
expression of ICAM-1 and VCAM-1 on the endothelium and the regulated 
phosphorylation of various proteins at the intercellular junctions (Luster et 
al. 2005). Also, molecules on the phagocyte surface interact with junctional 
molecules thus replacing the homophilic molecular interactions between 
adjacent endothelial cells. For instance, PECAM-1 (platelet/endothelial cell 
adhesion molecule 1) and CD11b/CD18 on a phagocyte interact with PECAM-1 
and JAM-C (junctional adhesion molecule C) on the endothelial junctions, 
respectively. Leukocyte integrins and the modification of the cytoskeleton 
drive the formation of lamellipodia, which the leukocytes use for crawling 
onwards. Following the passage of leukocytes, endothelial junctions are 
resealed (Imhof and Aurrand-Lions 2004).  
In the fourth step leukocytes migrate in the tissue towards the 
inflammatory focus. There the concentration gradient of extracellular matrix 
(ECM)-bound chemokines. The early-released IL-8 attracts mostly neutrophils, 
which usually peak within the first six hours of the response. Monocytes are 
predominantly recruited later e.g. through the release of MCP-1 (Janeway et 
al. 2005b). The use of PECAM-1 on leukocytes increases the avidity of specific 
1 and 2 integrins for ECM constituents. Also, in order to remodel and 
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penetrate ECM barriers, particular proteases and glycosaminoglycan-
degrading enzymes are upregulated in leukocytes. The localised proteolysis 
can also expose cryptic ECM ligands (Luster et al. 2005). Receptor recycling 
and clustering of anti-adhesive cell surface molecules (e.g. leukosialin) favour 
the detachment from adhesion substrates, which is also needed for moving 
(Witko-Sarsat et al. 2000).  
CD11b/CD18 
Integrins are adhesion molecules required for interactions of leuko-
cytes with endothelial cells, other cell types and ECM. Upon binding their 
ligands, integrins cluster and become activated, and signals generated by 
certain other cell surface receptors are also mediated to integrins to increase 
their ligand avidity. The intracellular targets of integrins include tyrosine 
kinases, MAP kinases, cytoskeletal components and adaptor molecules. The 
signalling events are coordinated to bring about the appropriate responses, 
foremost cell motility, growth, differentiation, survival and the specialised 
functions of phagocytes (Williams and Solomkin 1999).  
Each leukocyte subtype expresses one or more members of the 2 
integrin family. 2 integrins are heterodimeric glycoproteins consisting of 
either an L (CD11a), M (CD11b),X (CD11c) orD (CD11d) chain, and a 
common 2 chain (CD18). Within minutes after stimulation, CD11b/CD18 (M2 
or Mac-1) is increased on the plasma membrane of circulating phagocytes 
from cytoplasmic storages, and CD11b/CD18 can be used as an early and 
sensitive phagocyte activation marker (Repo and Harlan 1999). It is an 
extremely promiscuous receptor, being able to interact with over 30 protein 
and non-protein ligands (Table 5). Accordingly, it is utilised in all steps of 
phagocyte extravasation after tethering (Yakubenko et al. 2002). 
The major ligand-binding region of CD11b/CD18 is the so-called I 
(inserted) domain in the M chain, in which the consensus sequence forms a 
loop and a contiguous  helix (Figure 5). However, the molecular basis of the 
degenerate binding is poorly understood (Yakubenko et al. 2002). Some ligands 
of CD11b/CD18 can be competitive, and their spatial and temporal distribu-
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tion may determine which of them are primarily bound (Pluskota et al. 2003). 
A unifying feature of the ligands might be the presence of acidic residues 
positioned in a certain conformation (Harris et al. 2000, Stefanidakis et al. 
2003). The phosphorylation state of specific cytoplasmic  chain residues is 
likely to influence the conformation of the extracellular part and the binding 
preference for the endothelium or iC3b, for example (Fagerholm et al. 2006). 
Phagocyte functions 
Phagocytosis  
Upon phagocytosis, a phagocyte engulfs the microbial target into an 
intracellular vacuole, phagosome, which “matures” to form the “killing 
compartment”, where oxygen-dependent and -independent mechanisms are 
activated. In macrophages, the phagosome matures by fusing with endosomes 
and lysosomes acquiring lysosomal hydrolases and vacuolar ATPase, which 
creates optimal acidic conditions for the activity of the hydrolases (Lee et al. 
2003). In neutrophils, cytoplasmic granules are rapidly unloaded to the 
phagosome and plasma membrane (Allen 2003).  
Table 5. Examples of extracellular CD11b/CD18 ligands. 
 
Endothelial molecules Phagocyte enzymes 
   ICAMs 1-3    Elastase 
   E-selectin    Myeloperoxidase 
   Junctional adhesion molecule C (JAM-C)    Catalase 
Plasma proteins  Extracellular matrix proteins 
   Fibrinogen    Fibronectin 
   Kininogen    Laminin 
   Factor X    Collagens 
   Complement fragment iC3b    Vitronectin 
   Complement factor H    Matrix metalloproteinase-9 (MMP-9)  
   Transferrin Pathogen structures of  
    Bovine serum albumin      Candida albicans 
   Ovalbumin    Bordetella pertussis 
Leukocyte surface receptors    Leishmania 
   CD14 Non-proteins 
    Fc receptors (e.g. CD16)    Heparin 
   Urokinase-type plasminogen    -glucan 
   activator receptor    Plastic 
 
Yakubenko et al. 2002, Imhof and Aurrand-Lions 2004 (JAM-C) Fagerholm et al. 2006 
(MMP-9).  
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Phagocytosis is mediated by an array of different PRRs on a phagocyte 
that concomitantly interact with the target structure. Opsonisation, most 
importantly mediated by Fc receptors and, in innate immunity, complement 
receptors, is essential for recognising particles that are not immediate ligands 
for phagocyte receptors (Stuart and Ezekowitz 2005).  
 
 
Figure 5. Structure of 2 integrins. The  chain includes seven extracellular N-terminal 
homologous repeats with a  propeller structure. The lighter coloured regions in the hetero-
dimer represent the  chain I domain and the  chain I-like domain, each with the embedded 
metal ion-dependent adhesion site (MIDAS). The heterodimer is illustrated in the “closed”, 
i.e. low-affinity state. Quaternary changes triggered by activating signals shift the I-like 
domain, allowing the I domain to accept a more open, high-affinity state via tertiary changes.  
Adapted from Harris et al. 2000. 
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Oxygen-dependent antimicrobial response  
The NADPH oxidase complex is assembled and activated on the 
plasma membrane and within phagosomes as phagocytosis begins (Weiss 
1989). It catalyses the production of superoxide (.O2-), which particularly 
attacks bacterial enzymes involved in amino acid biosynthesis, and reacts 
further to produce stronger oxidants, hydrogen peroxide (H2O2) and hydroxyl 
radical (.OH). These attack microbial proteins, DNA and lipids (Miller and 
Britigan 1997).  
Myeloperoxidase (MPO) uses H2O2 and halides to produce hypohalous 
acids that peroxidate, oxidise and decarboxylate cell membranes and oxidise 
the respiratory chain (Miller and Britigan 1997). Hypochlorous acid reacts 
with amines to generate chloramines, some of which are especially long-lived 
oxidants (Weiss 1989). The MPO-H2O2 system also generates tyrosyl radicals 
and reactive aldehydes from substrates other than halide ions (Witko-Sarsat et 
al. 2000).  
Macrophages are considered to exhibit a less marked oxidative killing 
capacity than neutrophils primarily because of the significantly lower 
expression of MPO (Allen 2003). However, macrophages are able to produce 
nitric oxide (NO.), which interferes with the proteins of the respiratory chain 
and DNA synthesis machinery. It can also react further with .O2- to generate 
peroxynitrite (ONOO-) that oxidates DNA bases and peroxidates lipids (Miller 
and Britigan 1997). 
Oxygen-independent antimicrobial response  
The oxygen-independent response of phagocytes includes proteases, 
antimicrobial peptides and membrane-bound receptors for endothelial, 
extracellular matrix and bacterial ligands (Lee et al. 2003). In neutrophils, 
these are located in four types of cytoplasmic granules: azurophil (primary), 
specific (secondary) and gelatinase (tertiary) granules and secretory vesicles 
(Faurschou and Borregaard 2003). 
Following even a low-level inflammatory stimulation, secretory 
vesicles are exocytosed exposing, for example, CD11b/CD18 to its endothelial 
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ligands. Gelatinase granules have the second highest propensity for 
extracellular release, and their typical contents, matrix metalloproteases, are 
needed in extravasation. Specific granules and last, azurophil granules 
undergo partial exocytosis, unloading matrix-binding and -degrading enzymes 
and antimicrobial substances such as lysozyme. The contents of azurophil and 
specific granules are also released and activated in phagosomes containing 
bacterial structures (Faurschou and Borregaard 2003).  
The proteins of the host are protected from the action of neutrophil 
proteases by ubiquitous endogenous inhibitors. Sufficient phagocyte 
migration is apparently retained as the large inhibitors are excluded from the 
space between the phagocyte and ECM, and as serine proteases are bound on 
the phagocyte surface. The term “neutrophil proteases” is often used although 
low levels of elastase and cathepsin G are also produced in macrophages 
(Pham 2006). 
Resolution of inflammation 
In order to reach complete healing, the inflammatory response must be 
repressed. Data on neutrophils suggest that a coordinated resolution program 
initiates already during the first hours of the response as the pathways 
leading to PGE2 and PGD2 production also give rise to other classes of lipid 
mediators. These include lipoxins generated from arachidonic acid, and 
resolvins and protectins from omega-3 polyunsaturated fatty acids. Lipoxins 
retard the entry of neutrophils, reduce vascular permeability and stimulate 
macrophages to ingest apoptotic neutrophils. PGD2 and its metabolites 
override neutrophil survival signals, triggering caspase-dependent apoptosis 
(Serhan and Savill 2005).  
Macrophage activation is considered to comprise early pro-
inflammatory and later anti-inflammatory phases. Alternatively activated 
macrophages play a major role in all resolution: down-regulation of 
inflammation, angiogenesis, and elimination of tissue debris, apoptotic cells 
and bodies (Porcheray et al. 2005). The phagocytic removal of apoptotic cells 
not encouraging inflammation is essential for the re-establishment of tissue 
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homeostasis. Phagocytes that have engulfed apoptotic cells begin the 
production of cytokines such as VEGF, which is critical for the repair of 
endothelial and epithelial injury, and TGF-1, which suppresses TLR 
signalling (Serhan and Savill 2005). Reparatory macrophages produce intra-
cellular repressors of signal transduction, enzymes modifying chromatin 
structure, and inhibitors of signalling between cell surface receptors and pro-
teoglycans (Wells et al. 2005), and the resolution program ends as the macro-
phages withdraw and depart through the lymphatics (Serhan and Savill 2005). 
VEGF 
Vascular endothelial growth factor (VEGF) was first described as 
vascular permeability factor (VPF), the most potent promoter of vascular 
permeability and tumour-associated ascites fluid accumulation (Senger et al. 
1983), and thereafter, a factor essential for growth and differentiation of 
endothelial cells (Leung et al. 1989). VEGF stimulates angiogenesis (sprouting 
of new vessels from pre-existing vasculature) by promoting the migration of 
endothelial cells and vascular smooth muscle cells, and vasculogenesis by 
recruiting endothelial progenitor cells from the bone marrow. Of the several 
splicing variants of VEGF, a protein of 165 amino acids is the predominant 
and also the strongest isoform in stimulating angiogenesis (Byrne et al. 2005). 
The action of VEGF is needed in normal physiology and physiological 
responses. It is required in establishing the vascular network of an embryo. In 
addition to its angiogenic role in the healing of injured tissues or wounds, 
VEGF also promotes the migration of mononuclear phagocytes and 
neutrophils thus contributing to the acute inflammatory response. VEGF is 
also expressed in the female reproductive tract, being highest in the early 
development of the corpus luteum (Byrne et al. 2005). 
Elevated local and serum VEGF levels are associated with the 
pathogenic processes in certain diseases, e.g. excessive endothelial prolifer-
ation and joint destruction in the joints of patients with rheumatoid arthritis 
(Paleolog 2002), ocular neovascularisation and hemorrhages in patients with 
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diabetic retinopathy (Hoeben et al. 2004), and abnormal dermal blood vessels 
and reddening of the skin in patients with psoriasis (Xia et al. 2003).  
Tumour cells require nutrients and oxygen via blood vessels in order 
to grow beyond 2-3 mm3 in size. VEGF is also secreted by tumour cells and 
harnessed by them in building an intratumour vascular supply. VEGF also 
stimulates the migration and invasion of some tumour cells, which, together 
with the new vasculature of the tumour, facilitate the forming of distant 
metastases (Byrne et al. 2005). 
IFN-
Interferon- is a type I interferon and mainly produced by DCs, 
monocytes, macrophages, T cells, NK cells and fibroblasts. It is essential for 
innate antiviral defense and efficient in inhibiting neoplastic growth, and 
found to be a useful clinical immunotherapeutic. Its well-known effects on 
target cells include enhancement of antigen presentation by upregulating the 
processing of viral antigens and expression of MHC class I molecules, 
stimulation of NK cell-mediated cytotoxic activity, and induction of apoptosis 
by activating caspases and (in the presence of dsRNA) inhibiting translation. 
Furthermore, IFN--induced IFN- expression in CD4+ and CD8+ T cells and 
NK cells may be a nexus for the innate-to-adaptive transition. Identifying the 
specific or direct effects of IFN- is complicated because it regulates several 
other cytokines and their receptors (Brassard et al. 2002), and because IFN- 
can be induced by signalling routes that also lead to other immune genes, e.g. 
in the late phase of LPS-induced signalling, including IRF-3 and IFN- 
induction (Hata et al. 2002) (Figure 2).  
In acute inflammation, high levels of IFN- may promote the responses 
that protect the host (e.g. activation of regulatory T cells, reduction of the TNF 
response to LPS, and increase of redox reactions that prevent oxidative 
stress). Interestingly, when the inflammatory stimuli are becoming overcome, 
the lowering of IFN- levels may provide a signal for major shift to non-
inflammatory state. Low IFN- levels decrease the cell surface expression of 
CD14 and other PRRs, for example (Amadori 2007). IFN- also inhibits 
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angiogenesis (Brassard et al. 2002) and thus, the decline in IFN- levels in the 
healing process may contribute to the induction of angiogenesis. On the other 
hand, higher IFN-levels could counteract angiogenic pathophysiology. 
Systemic inflammation 
Systemic inflammation is a consequence of the activation of innate 
immunity throughout the circulation, i.e. systemically. If the local response 
fails to limit the pathogen, it can spread into the bloodstream and the 
condition is called sepsis. Hereby, TNF is released by macrophages in the 
liver, spleen and other organs and tissues. This leads to systemic increase in 
vascular permeability with subsequent tissue edema, loss of plasma volume 
and eventually, shock. As disseminated blood clotting is also triggered by 
TNF, the clotting factors are consumed massively, and the ability to clot 
appropriately when needed is lost. This often leads to bleeding and failure of 
vital organs such as the kidneys, liver, heart and lungs (Janeway et al. 2005b). 
The mortality in septic shock is high, 50-90%. In such a critical state as sepsis, 
even the anti-inflammatory mechanisms aimed at resolution can be fatal, 
because they may lead to immune suppression, which increases the risk of 
secondary infections and organ failure (Takala et al. 2002).  
GENETIC VARIATION 
Single nucleotide polymorphisms (SNPs) 
SNPs are defined as base pair positions in DNA at which the rarest 
alternatives (alleles) exist at least in 1% of normal individuals. Thus they are 
the most common type of genetic variation in humans. An SNP occurs in 
approximately 1 of 1000 base pairs, depending on the genome region. 
Mechanisms that modify demographic history, such as selective pressure 
from infectious microbes (Aguillón et al. 2006), bottlenecks, admixture, 
inbreeding, migration, immigration and assortative mating have produced 
distinctive inheritable SNP patterns in different populations (Brookes 1999).  
SNPs are said to be functional if they affect gene products and 
biological processes. First, when an SNP in the coding region causes an amino 
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acid change, the structure and function/activity of the corresponding protein 
can be altered. Second, promoter SNPs that modulate the binding affinity of 
transcription factors potentially influence gene expression levels. Third, 
variation in the 5’ untranslated region (UTR) may disrupt mRNA translation, 
and variation in the 3’ UTR may affect mRNA stability and export. Fourth, 
changes in the reading frame or preterm transcription termination signals 
usually lead to a defective or truncated protein. Finally, splice site changes 
can interfere with mRNA processing or protein function (Arcaroli et al. 2005). 
SNPs in innate immune genes may influence the risk, activity, and 
adaptive downstream responses of diseases with an inflammatory component 
(Lazarus et al. 2002). Usually, the combination of SNPs and environmental 
factors has the potential to determine disease appearance (Brookes 1999). 
TLR4 +896AG 
The human TLR4 gene contains 44 SNPs (Lazarus et al. 2002). Of these, 
the +896AG substitution leads to the Asp299Gly change in the extracellular 
domain of the TLR4 protein. This may reduce LPS-mediated cellular 
responses, possibly by impairing ligand binding or by disturbing the 
transport of TLR4 to the cell surface (Arbour et al. 2000, Kiechl et al. 2002). 
TLR4 +896G is associated with inflammatory conditions (Table 6), e.g. 
increased risk of Gram-negative infections (Agnese et al. 2002) and septic 
shock (Lorenz et al. 2002) and in some cases, recognition of ligands other than 
LPS (e.g. Chlamydial or endogenous heat-shock proteins, oxidised lipids) 
(Edfeldt et al. 2004, Schröder and Schumann 2005).  
CD14 -159CT 
37 SNPs have been identified within the human CD14 gene (Lazarus et 
al. 2002). The -159CT exchange in its promoter region may be associated 
with increased transcriptional activity, probably by weakening the 
interaction between the so-called GC box and the inhibitory transcription 
factor Sp3 (Le Van et al. 2001). -159T was first reported to be a risk factor for 
myocardial infarction (Unkelbach et al. 1999). Thereafter, it has been 
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associated with several inflammatory diseases (Table 7), e.g. Gram-negative 
infections (Sutherland et al. 2005). CD14 can also be linked to adaptive TH2 
responses in allergy. Low LPS exposure in early childhood may predispose to 
Table 6. Studies investigating the potential association of inflammatory conditions 
with the TLR4 +896G allele. 
 
Condition Association Population studied Reference 
Gram-negative infection Risk  Combined American Agnese et al. 2002 
Septic shock  Risk  White French Lorenz et al. 2002 
Meningococcal disease NS Gambian Allen et al. 2003 
RSV infection Risk  Israeli Jewish Tal et al. 2004 
Crohn’s disease (CD) and 
ulcerative colitis (UC) 
Risk  
 
CD: Risk , UC: NS 
Belgian, Ashkenazi 
Jewish, Moroccan 
Dutch 
Franchimont et al. 2004 
 
Braat et al. 2005 
Asthma Risk  Swedish Fagerås-Böttcher et al. 2004 
Atherosclerosis Progression  Italian Kiechl et al. 2002 
Cardiovascular events Risk  Dutch Boekholdt et al. 2004 
Myocardial infarction NS 
Risk  in men 
White American men 
Swedish 
Zee et al. 2005 
Edfeldt et al. 2005 
Spondyloarthropathies NS Hungarian Gergely et al. 2006 
Rheumatoid arthritis NS Spanish Sánchez et al. 2003 
SLE NS Spanish Sánchez et al. 2003 
Diabetic neuropathy Risk  White German Rudofsky et al. 2004 
 
NS, not significant; RSV, respiratory syncytial virus; SLE, systemic lupus erythematosus. 
 
 
 
Table 7. Studies investigating the potential association of inflammatory conditions 
with the CD14 -159T allele. 
 
Condition Association  Population studied Reference 
Myocardial infarction Risk  in subjects w/o 
other risk factors 
White German men Unkelbach et al. 1999 
Acute coronary syndromes Risk   (TT 
homozygotes) 
White British men Arroyo-Espliguero et al. 2005 
Atopic asthma Risk  Indian Sharma et al. 2004 
Atopy Children: Risk , 
adults: NS 
NS 
Australian 
 
Swedish 
O’Donnell et al. 2004 
 
Fagerås-Böttcher et al. 2004 
Gram-negative infections Risk  White Canadian  Sutherland et al. 2005 
Septic shock Risk , mortality  White French Gibot et al. 2002 
Crohn’s disease Risk  
NS 
German 
Hungarian 
Klein et al. 2002 
Klausz et al. 2005 
Ulcerative colitis Risk  Japanese Obana et al. 2002 
Rheumatoid arthritis NS White German de la Fontaine et al. 2005 
Parkinson’s disease Risk  (TT homo-
zygous women) 
Taiwanese Lin et al. 2006 
Alcoholic liver disease Risk  Finnish Järveläinen et al. 2001 
 
w/o, without; NS, not significant. 
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high IgE production with concomitant susceptibility to allergic disorders 
(Sharma et al. 2004). -159TT homozygotes seem to have increased sCD14 levels, 
paralleled by decreased IgE levels (Baldini et al. 1999).  
TNF promoter polymorphisms 
At least 7 distinct SNPs are located within the proximal promoter of 
the TNF gene (Flori et al. 2005). Positions -308, -238 and -376, for example, may 
be functional. -308G/A was the first TNF SNP discovered, and several studies 
have confirmed that the A allele increases stimulated and unstimulated TNF 
production at transcriptional (Wilson et al. 1997, Abraham and Kroeger 1999) 
and translational level (Louis et al. 1998). -238G/A is located near a repressor-
binding site (Flori et al. 2005) and -376G/A within a region capable of multiple 
Table 8. Studies investigating the potential association of disease conditions with 
TNF promoter SNPs. 
 
SNP Disease Association  Population 
studied 
Reference 
 -308A Malaria Risk and mortality  Gambian  McGuire et al. 1994 
Septic shock Risk and mortality  
Mortality  
NS 
White French  
Chinese 
White British and 
Australian 
Mira et al. 1999 
Zhang et al. 2003 
Gordon et al. 2004 
Rheumatoid arthritis Risk , severity  
NS 
Swedish 
Polish 
Cvetkovic et al. 2002 
Pawlik et al. 2005 
Psoriasis, PsA Risk   Estonian Mössner et al. 2005 
Irritable bowel sdr. Risk  Dutch van der Veek et al. 2005 
Metabolic syndrome Risk  Combined Sookoian et al. 2005 
Non-Hodgkin lymphoma Mortality  French Juszczynski et al. 2002 
Hepatocellular ca. Risk  Taiwanese Ho et al. 2004 
 -238A Rheumatoid arthritis Severe disease  
Joint erosions  
Italian 
Dutch 
Fabris et al. 2002 
Brinkman et al. 1997 
Psoriasis  
Psoriasis, PsA 
Risk  Estonian 
German 
Mössner et al. 2005 
Höhler et al. 1997 
Ankylosing spondylitis NS Dutch Kaijzel et al. 1999 
Uveitis  Risk  Austrian El-Shabrawi et al. 2005 
SLE Risk  Mexican Mestizo Zúniga et al. 2001 
Malaria Parasitemia  Burkinabe Flori et al. 2005 
 -376A Malaria Severe disease  Gambian, Kenyan Knight et al. 1999 
 
SNP, single nucleotide polymorphism; PsA, psoriatic arthritis; sdr., syndrome; ca., 
carcinoma; SLE, systemic lupus erythematosus; NS, not significant. 
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DNA-protein interactions (Knight et al. 1999). Disease conditions with which 
TNF SNPs might be associated include malaria, septic shock and rheumatoid 
arthritis (Table 8). 
INFLAMMATORY RHEUMATIC DISEASES 
JOINTS 
Normal anatomy 
Joints are the structures connecting bones. Synovial joints are those 
that allow the movements of the limbs, support in exercise and have a 
synovial cavity between the adjacent bones (Figure 6). Immovable (e.g. 
sutures of the skull, and the sacrum) or slightly movable joints (e.g. those 
between the vertebrae) provide support and protection, and contain 
connective tissue, cartilage or bone tissue between the bones (Mankin and 
Radin 1989). 
The synovial joint is surrounded by the synovial capsule composed of 
the outer collagen-rich fibrous joint capsule (e.g. forming the ligaments that 
guide the direction and magnitude of movements) and the inner synovial 
 
Synovial capsule 
Fibrous joint capsule 
Synovial membrane 
Synovial cartilage 
Bone 
Synovial cavity 
Periosteum 
Figure 6. Parts of the synovial joint. Helminen and Tammi 2002. 
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membrane (Figure 8). The main cells of the synovial membrane, synoviocytes, 
are either macrophage- or fibroblast-like and surrounded by glycosamino-
glycans and thin fibres of connective tissue. The synovial cavity normally 
contains only a few milliliters of synovial fluid that acts as a lubricant and 
nourishes the cartilage that has no blood vessels. The highly hydrophilic 
hyaluronate makes the fluid gel-like. In the cartilage matrix, large aggregates 
of hyaluronate and proteoglycans (typically aggrecan) give elasticity and 
diminish friction. Their anionic groups attract cations, increasing osmotic 
pressure and promoting elasticity. The collagen framework surrounding the 
aggregates gives tensile strength (Mankin and Radin 1989). 
Pathologic changes 
The first inflammatory changes in the joint are tissue edema and 
fibrin deposition. When the synovitis continues, the synovial membrane 
thickens, consisting of layers of synoviocytes and inflammatory cells. Early in 
the chronic disease, endothelial cells of synovial vessels transform into high 
endothelial venules, which are normally found in secondary lymphoid organs. 
Active angiogenesis provides the hypertrophic synovium with oxygen, 
nutrients and additional inflammatory cells (Lee and Weinblatt 2001). VEGF 
and its receptor are present in the rheumatoid synovium (Müller-Ladner et al. 
2005). 
Pannus, i.e. hypertrophic synovial membrane growing over the 
cartilage surface, is a characteristic rheumatic lesion. By time, the 
incongruence and destruction of the synovial surfaces, muscle pull and 
damages of the capsule, ligaments and tendons cause the typical deformities. 
Spreading of pannus-like tissue into periarticular tissues leads to ankylosis of 
the joint (Hough and Sokoloff 1989). 
Cartilage degradation is started by the activity of proteases, which 
cleave proteoglycans from the matrix, impairing the tissue’s mechanical 
capacity. This damage can still be reversed by proteoglycan synthesis of 
chondrocytes. In turn, collagen degradation, performed by metalloproteases, 
is thought to be irreversible (Zvaifler 1989). 
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The balance of bone formation/degradation is shifted towards 
degradation in chronic joint inflammation. The bone-resorbing cells, 
osteoclasts, are equipped with enzymes and a proton pump that enable them 
to degrade bone matrix and solubilise calcium, respectively (Schett 2007).  
There are numerous pain nerve endings, nociceptors, throughout the 
joints (with the exception of the cartilage). Inflammatory mediators, cartilage 
destruction products and edema-associated intra-articular pressure sensitise 
the nociceptors to normal movements. Many mediators also excitate the 
nerves, and proteases can evoke spontaneous neural activity (McDougall 
2006). 
SPONDYLOARTHROPATHIES 
Spondyloarthropathies (SpAs) are a heterogeneous group of 
inflammatory diseases characterised by peripheral oligoarthritis, spinal 
inflammation, enthesitis (inflammation of attachments of ligaments or 
tendons to bones) and, at times, mucocutaneous, ocular and/or cardiac 
manifestations. SpAs show striking familial aggregation and are typically 
associated with the HLA-B27 allele, but their pathogenesis is not fully 
understood. SpAs include ankylosing spondylitis (AS), reactive arthritis 
(ReA), psoriatic arthritis (PsA), enteroarthritis/spondylitis associated with 
inflammatory bowel diseases (IBDs), juvenile spondyloarthropathy, and 
undifferentiated spondyloarthropathy encompassing patients who express 
features of other SpAs still not fulfilling their criteria. Isolated acute anterior 
uveitis and spondylitic heart disease associated with HLA-B27 can also be 
classified as SpAs (Reveille and Arnett 2005). 
SpAs are quite common, occurring in approximately 2% of the 
population, at least, as especially the undifferentiated form often remains 
underrecognised (Stafford and Youssef 2002). In Finland, the incidence of 
SpAs in adults is 218/100 000 annually. The most typical age of onset lies 
between 20 and 40 years (Isomäki et al. 1978).  
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Diagnosis and clinical manifestations 
The lower extremities of the body are typically affected in SpAs, and 
the pattern of inflamed joints is asymmetrical. Enthesitis, such as Achilles 
tendonitis or plantar fasciitis, is an important hallmark. Widely accepted 
diagnostic criteria are shown in Table 9. Radiological sacroiliitis develops 
slowly and therefore, is usually not helpful in early diagnosis (Stafford and 
Youssef 2002).  
There are no specific laboratory tests for diagnosing SpAs. Findings 
supporting the SpA diagnosis include HLA-B27 positivity, absence of 
rheumatoid factor, elevation of the erythrocyte sedimentation rate (ESR) or 
CRP level, and anemia (Kataria and Brent 2004). 
Reactive arthritis (ReA) is usually a mild form of SpA with a self-
limiting course of 3-12 months. It is an aseptic arthritis developing 1-4 weeks 
after an infection outside the joints, usually in the gastrointestinal or genito-
urinary tract. Up to 50% of the patients have extra-articular manifestations, 
such as conjunctivitis. The triad of urethritis, conjunctivitis and arthritis is 
called Reiter’s syndrome. Dactylitis (“sausage digit”, inflammation of an 
entire digit) is also common (Kataria and Brent 2004). When ReA following an 
intestinal infection is suspected, bacterial culture finding is of high diagnostic 
value but only received when the pathogen is still present in the intestine 
(Leirisalo-Repo 2005).  
Table 9. The criteria for diagnosing spondyloarthropathies according to the European 
Spondyloarthropathy Study Group (ESSG). 
     
Inflammatory spinal pain or synovitis (asymmetrical, predominantly in the lower limbs), and 
one or more of the following 
   Positive family history 
   Psoriasis 
   Inflammatory bowel disease 
   Urethritis, cervicitis or acute diarrhoea within 1 month before arthritis 
   Buttock pain alternating between right and left gluteal areas 
   Radiological sacroiliitis 
   Enthesopathy 
 
Dougados et al. 1991. 
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Ankylosing spondylitis (AS) is the most HLA-B27 -dependent (up to 
95% of the patients), severe and chronic form of SpA. It is three times more 
common in men than in women. Typically, it begins before the age of 30 with 
inflammatory lower back pain, which is worst in the early morning and 
improves with activity. Pain progresses upwards the spine and is relieved by 
stooping. Consequently, the spine may ossify into a kyphotic position. A 
totally ossified, rigid spine is seen in radiographs as “bamboo spine” (Kataria 
and Brent 2004). Acute anterior uveitis is the most frequent extra-articular 
manifestation. AS complicated by spinal fracture, cardiovascular and 
intestinal diseases or amyloidosis (which is becoming less common) is 
associated with increased mortality. However, AS is highly variable and may 
also heal (Khan 1998a).  
Pathogenesis  
The exact pathogenic mechanisms of SpAs are unknown. It is likely 
that an interplay between genetic, environmental and immunological factors 
is responsible for the clinical manifestations (Kataria and Brent 2004).  
Triggering bacteria 
So far, ReA is the only SpA whose pathogenesis has been proved to 
involve specific microbes. These are able to invade mucosal surfaces and 
replicate intracellularly and have LPS in their outer membrane (Reveille and 
Arnett 2005) (Table 10). Yersinia, typically contaminating pork, can grow at 
refrigeration temperature and induces a remarkable proportion of 
enteroarthritis in countries where food is stored in the fridge. As tourism is 
increasing, ReA following a Salmonella- or Campylobacter-induced food 
poisoning is becoming more common. Over 80% of Salmonella enteritis cases 
in Finland have been acquired abroad (Vesikari 2003). Campylobacter, usually 
growing in incorrectly handled or raw poultry products (Moore et al. 2005), is 
the most frequent trigger of enteroarthritis. Chlamydia trachomatis causes 
the common sexually transmitted disease and is also the most common trigger 
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of uroarthritis and ReA altogether. On the whole, 1 to 15% of those having a 
mucosal infection develop arthritis (Leirisalo-Repo 2005). 
Antigens of ReA-associated microbes have been detected in the 
synovium of ReA patients even years after the initial infection, suggesting a 
pathogenic role for prolonged bacterial persistence. Circulating IgA 
antibodies and synovial T cell response against the initial microbe have also 
been observed (Reveille and Arnett 2005). As IgA antibodies are typical of 
mucosal defence, the hypothesis of the association between inflammation in 
the joints and colonic mucosa is supported (Figure 7). Intestinal bacterial 
antigens may be circulated by mononuclear phagocytes between the gut and 
joints (Baeten et al. 2002b) and the breakdown of the gut-blood barrier could be 
an inciting or/and perpetuating event in SpAs (Reveille and Arnett 2005).  
Genetic predisposition 
In 1973, HLA-B27 was reported to be strongly associated with AS 
(Brewerton et al. 1973, Schlosstein et al. 1973) and to date, it is the only 
documented susceptibility gene for other SpAs, too (Breban et al. 2006) (Table 
11). The frequency of HLA-B27 in a given population loosely correlates with 
the frequency of SpAs. For instance, 40% of the Alaskan Eskimos, 24% of the 
Table 10. Microbes associated with reactive arthritis.  
 
Enteroarthritis  
   Campylobacter 
   Salmonella 
   Yersinia    
   Shigella (mostly Sh. flexneri) 
   Clostridium difficile (rare) 
Uroarthritis  
   Chlamydia trachomatis 
   Neisseria gonorrhoeae (?) 
  Mycoplasma genitalium (?)  
  Ureaplasma urealyticum (?) 
Arthritis following an upper respiratory tract infection 
   -haemolytic streptococci (more usually triggering rheumatic fever) 
   Chlamydia pneumoniae 
 
Modified from Leirisalo-Repo 2005. 
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Sami and 8% of the caucasoids in Western Europe and the USA are B27 
positive with the AS frequency being 2.5%, 1.8% and 0.2%, respectively (Khan 
1998b).  
HLA-B molecules belong to the MHC class I proteins, which are 
expressed on all normal nucleated cells as heavy chain - 2 microglobulin 
heterodimers. The classical function of MHC class I proteins is to present 
Figure 7. Evidence of the association between spondyloarthropathies (SpAs) and 
inflammation in colonic mucosa. ReA, reactive arthritis. References: Söderlin et al. 1999, 
the reviews by Baeten et al. 2002a, Reveille and Arnett 2005. 
 
 
Table 11. Percentage of HLA-B27 positive individuals of patients with 
spondyloarthropathies in Europe. 
Ankylosing spondylitis 95% 
Reactive arthritis 70% 
Psoriatic spondylitis 60% 
Peripheral psoriatic arthritis 25% 
Inflammatory bowel disease –associated spondylitis 70% 
Acute anterior uveitis without other stigmata of spondyloarthropathies 50% 
 
Reveille and Arnett 2005. 
 
 
Gut:  
- 25-75% of patients with SpA: subclinical gut 
lesions, which may evolve to clinically overt 
Crohn’s disease  
-Impaired TH1 cytokine production in SpA  
and Crohn’s disease 
 
Circulation: 
-IgA antibodies against ReA-associated 
microbes in ReA patients 
Joints: 
-Presence of antigens from enteroarthritis- 
associated microbes (even years after 
the initiating infection) 
-T cell proliferation against the initiating 
microbe 
-Gut-derived immune cells from patients 
with inflammatory bowel disease can home 
to the joints 
-C. difficile, a bacterium of normal flora, can  
trigger ReA as a reaction to antibiotics 
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intracellularly produced foreign (i.e. viral, bacterial or tumour) peptides to 
CD8+ T cells and to activate killing-inhibiting receptors on NK cells so that 
only abnormal cells become killed (Reveille and Arnett 2005). HLA-B27 is one 
of around 490 polymorphic HLA-B alleles recognised. Polymorphism is 
concentrated in regions involved in peptide binding (Chaplin 2003). However, 
it is not known how HLA-B27 increases the risk of SpAs and why it is only 
associated to certain organ systems (Reveille and Arnett 2005). The most 
studied hypotheses are the arthritogenic peptide and molecular mimicry 
theories (Table 12). 
According to the arthritogenic peptide hypothesis, HLA-B27 has a 
unique ability to bind a joint-specific peptide recognised by autoreactive CD8+ 
T cells. The molecular mimicry hypothesis suggests that bacterial peptides 
and either an HLA-B27 peptide or a self peptide presented by HLA-B27 may 
cross-react, which could break tolerance. More recent theories bring up the 
amino acid residues in the B pocket of HLA-B27, which predispose to slow or 
incorrect folding during the B27 assembly in the endoplasmic reticulum (ER). 
Thereby, two heavy chains tend to form homodimers, which could induce 
proinflammatory ER stress (Hacquard-Bouder et al. 2006). Free heavy chains 
that still have the peptide-binding groove may also be expressed on the cell 
Table 12. Hypotheses to explain the role of HLA-B27 in spondyloarthropathies. 
 
Hypothesis Implication of HLA-B27 Immunological mechanism 
Antigen-specific 
Arthritogenic 
peptide 
Presentation of self peptide  
deriving from target tissue  
antigen 
Activation of autoreactive CD8+ T cells 
against self peptide 
Molecular mimicry Mimicry between self 
peptide derived 
from/presented by HLA-B27 
and bacterial antigen 
Cross-reaction between bacteria 
responsible for infection and HLA-B27 
Independent of antigen specificity 
Misfolding Slow folding of HLA-B27 in 
the endoplasmic reticulum 
Instability of HLA-B27, stress response, 
NFB activation, inflammatory response 
HLA-B27 heavy 
chain dimerisation 
Disulfide bond formation 
between 2 cysteine 67 
Unusual reactivity between HLA-B27 and 
CD4+ or natural killer cell receptors 
 
Hacquard-Bouder et al. 2006. 
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surface. Altogether, SpAs may be associated with the recognition of different 
HLA-B27 forms by leukocyte receptors (Reveille and Arnett 2005).  
According to family studies, HLA-B27 contributes to about 37% of the 
overall genetic risk of SpA. The entire effect of the MHC region is 50%, 
including genes that encode e.g. HLA-DR proteins of MHC class II, TNF, 
complement components, heat shock protein 70, and proteins involved in 
antigen presentation by MHC class II molecules. Evaluation of the effect of 
individual loci is complicated by strong linkage disequilibrium and HLA-B27 
(Reveille and Arnett 2005, Breban et al. 2006) and the fact that the risk alleles 
are apparently associated with specific symptoms rather than SpA subtypes 
(Breban et al. 2006).  
Genome-wide scans have revealed non-MHC regions that may contain 
SpA-associated genes. A significant association has been found between AS 
and the IL-1 gene cluster in chromosome 2. Currently, the most promising 
region is probably the 9q31-34 (Breban et al. 2006). 
Innate immune responses 
The synovium and entheses of the SpA patients are rich in T cells, 
particularly CD8+ cells (Baeten et al. 2002a). However, synovial infiltration of 
phagocytes may reflect the global disease activity of SpAs, and the innate 
immune cells play a prominent role in SpA synovitis while lymphocytes cause 
only secondary alterations (Baeten et al. 2005). Macrophages expressing the 
haptoglobin scavenger receptor CD163 are abundant in the synovium of SpA 
patients. Cross-linking of CD163 mediates e.g. the secretion of IL-6 and GM-
CSF (Baeten et al. 2002b), and CD163+ cells exhibit high HLA-DR expression 
and TNF production after LPS stimulation. Chronic exposure to high levels of 
TNF can lead to impairment of TH1 response and insufficient clearance of 
intracellular bacteria. Consistently, the use of TNF blockers has provided 
very beneficial effects on arthritic symptoms in AS, PsA and undifferentiated 
SpA, and on enthesitis and uveitis (Baeten et al. 2002a).  
Self molecules characteristic of the joints, such as proteoglycans, have 
been proposed to activate TLR4 signalling, and peripheral blood mononuclear 
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cells from SpA patients can have a nearly 50% increase in TLR4 expression 
when compared with healthy individuals (De Rycke et al. 2005). Intact 
extracellular matrix may inhibit TLR4 activation, and the inhibition is 
abrogated when proteases are released upon infection- or tissue injury-
triggered matrix degradation. LPS may also bypass the suppressive 
mechanism (Brunn et al. 2005). 
Treatment and outcome 
The treatment of SpAs includes patient education, physical therapy, 
exercise and most importantly, relief of pain and stiffness in which non-
steroidal anti-inflammatory drugs (NSAIDs) are usually effective. Disease-
modifying antirheumatic drugs (DMARDs, especially sulphasalazine and 
methotrexate) quite commonly cause adverse effects, and are therefore 
reserved for the patients who do not benefit from NSAIDs or who develop 
erosions. Intra-articular corticosteroid injections can be used to control local 
synovitis and relieve pain (Stafford and Youssef 2002). The use of the new and 
expensive biological drugs, TNF blockers, is considered when refractory 
active disease does not respond to traditional drugs (Reveille and Arnett 2005). 
There are probably no living bacteria in the joints of ReA patients and 
consistently, long-term antibiotics are not advantageous (Baeten et al. 2002a). 
15-30% of ReA patients develop chronic arthritis or radiologically 
detectable sacroiliitis (Kataria and Brent 2004). The prognosis is slightly 
worse in uro- than enteroarthritis. Therefore, early diagnosis and treatment 
of C. trachomatis infection is essential. Genotyping of HLA-B has a prognostic 
value, since HLA-B27 positivity is often associated with a more difficult acute 
ReA, extra-articular symptoms, and development of chronic disease and 
spinal inflammation (Leirisalo-Repo 2005). Currently, early diagnosed AS only 
seldom results in severe disability. Patients with hip joint involvement or 
kyphotic spine have a worse prognosis (Khan 1998a). 55% of undifferentiated 
SpA patients and 17% of PsA patients have reached remission after 2-3 years 
(Stafford and Youssef 2002). Patients with polyarticular form of early PsA are 
at risk of progressive disease (Gladman et al. 2005) IBD-associated SpA usually 
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subsides in 6-8 weeks and only 10% develop chronic arthritis (Kataria and 
Brent 2004). There are quite few studies on the outcome of juvenile SpA, but it 
seems that more than 50% of the patients have active arthritis still in the 
adulthood (Minden et al. 2000).  
RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a systemic inflammatory disease 
characterised by chronic synovial joint inflammation that leads to cartilage 
and bone destruction (Aguillón et al. 2006). Despite the highly varying activity 
of RA, the disease frequently causes deformities of the joints, functional 
disability and sometimes extra-articular manifestations such as rheumatoid 
nodules, vasculitis, schleritis, pleuritis, pneumonitis, pericarditis, and ocular 
and haematological disorders (Lee and Weinblatt 2001). The primary cause 
and pathogenesis of RA remain unresolved. In general, it is defined as a result 
of a sustained immune response to an unknown antigen in a genetically 
susceptible host (Aguillón et al. 2006).   
RA affects approximately 1% of the adult population worldwide, being 
most common among Pima and Chippewa Indians in North America, and 
rarest in rural Africa (Lee and Weinblatt 2001). Its prevalence in Finland is 
0.8% with the incidence of 5000/100 000 adults each year. The typical age of 
onset lies between 60 and 70 years, and RA is three times more common in 
women than in men (Isomäki et al. 1978).  
Diagnosis and clinical manifestations 
The onset of RA is usually insidious, although a rapid multisystem 
inflammation is also possible. The predominant symptoms are pain, swelling 
and stiffness of peripheral joints (e.g. feet, fingers, wrists and knees are 
commonly affected), palpation tenderness, and morning stiffness caused by 
edema that accumulates in the tissues during sleep. Non-specific symptoms 
(tiredness, loss of appetite and weight) may also occur (Lee and Weinblatt 
2001). The diagnostic criteria used worldwide are shown in Table 13. 
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Serum autoantibodies are common in RA. The classic example, 
rheumatoid factor (RF), is present in 70-80% of the patients. It may appear 
years before the clinical symptoms take place, and permanent RF 
seropositivity is useful in distinguishing RA from other rheumatic conditions. 
RF recognises altered, aggregated or immunocomplexed mammalian IgG. 
However, RF is not a very specific marker for RA. Instead, novel and more 
efficient diagnostic tools, anti-citrullinated protein antibodies (ACPAs), are 
highly specific for RA, easily detected by citrullinated substrate constructs 
and good predictors of progressive joint damage (Weissmann 2006). 
ACPAs attack epitopes in which arginine residues have been 
converted to citrulline by peptidyl deiminase (PAD) enzymes (Cantaert et al. 
2006). Other post-translational modifications may also create epitopes 
contributing to the autoreactivity in RA. The patients often have 
autoantibodies against cartilage collagen, the arthritogenity of which may be 
attributed to glycosylation (Fournier 2005). In practice, a seropositive 
polyarthritis with radiologic erosions, unclear etiology, and existence of 
serum autoantibodies is regarded as RA, even if the clinical symptoms were 
minor (O’Dell 2004). 
Pathogenesis 
The disease process of RA has been proposed to consist of three phases 
(Table 14). Phases 2 and 3 are regarded as a TH1-type disease (Arend 2001). This 
is supported by the fact that in patients with RA and AIDS, RA can entirely 
Table 13. Diagnostic criteria for rheumatoid arthritis established by American 
College of Rheumatology in 1987. Four or more of the criteria should be fulfilled, and the 
criteria 1-4 must have been present for at least six weeks.  
 
1. Morning stiffness (for at least 1 hour) 
2. Arthritis of 3 or more joint areas 
3. Arthritis of hand joints 
4. Symmetric arthritis 
5. Rheumatoid nodules 
6. Rheumatoid factor in the serum 
7. Radiological changes (e.g. erosions) in hand and/or wrist joint 
 
Arnett et al. 1988. 
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heal when the number of CD4+ T cells declines as AIDS progresses (Weyand 
and Goronzy 1992). However, in RA, a high proportion of the synovial 
leukocytes are innate immune cells and the prevailing cytokines are derived 
from monocytes and macrophages (Lee and Weinblatt 2001). Furthermore, T 
cell activation in the synovium appears to be B cell-dependent (Müller-Ladner 
et al. 2005).  Thus, multiple cell types and mechanisms and factors influencing 
these are likely to contribute to the pathogenic process of RA. 
Several environmental and genetic factors have been associated with 
increased or decreased risk of developing RA. Interactions between these 
factors may be highly important, though mostly unknown as yet (Oliver and 
Silman 2006).  
Environmental factors 
According to the most common view, an infection is the 
environmental component needed to launch the inflammatory process in RA, 
and the most consistent evidence points to Epstein-Barr virus (EBV). RA 
patients may exhibit a decreased T cell response to the EBV protein gp110, 
which controls EBV replication. Such an insufficient response could lead to 
poor control of the infection and chronic exposure to EBV antigens. However, 
Table 14. Phases of the pathophysiology in rheumatoid arthritis. The initial phase may 
be largely subclinical and multiple mechanisms are possible. In the perpetuation phase, 
adaptive immunity is launched.   
 
Initiation 
Mechanisms are unknown 
May include local cytokine release by non-specific activation of resident macrophages and  
dendritic cells in the joints 
Perpetuation 
Priming of autoreactive T cells in lymph nodes  migration  activation of memory T cells 
within the joints 
Subsequent stimulation of B cells and macrophages with rheumatoid factor production and  
further cytokine release      
Chronic inflammation 
Dysregulation of multiple immune cell types 
Abnormal fibroblast growth 
T cell responses to altered self antigens 
 
Arend 2001.  
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any specific infection has not been confirmed to precede the onset of RA. 
Instead, there is indirect evidence of the involvement of different micro-
organisms. First, as there is similarity between human and microbial 
molecules (e.g. heat shock proteins), the immune system may fail in 
maintening tolerance, leading to autoimmune reactions (Oliver and Silman 
2006). Second, pet ownership has been suggested to be a risk factor, as pets are 
believed to harbour environmental agents that can trigger RA. Animal 
antigens per se, however, are an unlikely risk factor, as RA is more common 
in urban than in rural populations. Third, the recent decline in RA incidence 
in high-risk populations might reflect the changing of the habits of life, e.g. 
the intestinal flora is encountered by different pathogens than before 
(Aguillón et al. 2006).  
Smoking is one of the most studied lifestyle risk factors for RA. Males 
have an almost three-fold risk of developing RA if they are smokers, and 
heavy smoking can increase the risk of both sexes over 10-fold (Oliver and 
Silman 2006). Of the occupational exposures, inhaled silica particles may 
increase the risk of RA among rock drilling and stone crushing crew, 
presumably via the activation of alveolar macrophages (Stolt et al. 2005). 
Mineral oils cause polyarthritis in rats and increase the risk of RA among 
men exposed to motor or hydraulic oil. In rats, mineral oil is rapidly 
transported to the lymph nodes and may also trigger acute phase reactions 
(Svelander et al. 2001).  
Diet can affect the onset and persistence of RA. The so-called 
Mediterranean diet containing plenty of oily fish rich in omega-3 fatty acids 
may protect against inflammation, and antioxidants from fruit and vegetables 
may strengthen the advantageous effect (Oliver and Silman 2006). 
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Genetic predisposition 
Based on large twin studies in the UK and Finland, heredity accounts 
for around 50-60% of the predisposition to RA (Oliver and Silman 2006). Ethnic 
differences in haplotype distribution and linkage disequilibrium complicate 
the discovery of the ultimately responsible genetic factors (van der Helm-van 
Mil et al. 2005). Known risk genes/alleles for RA are listed in Table 15.  
Table 15. Examples of genes affecting the susceptibility or severity of rheumatoid 
arthritis. 
  
Genetic factor Proposed role in 
the pathogenesis 
Remarks References 
HLA-DRB1 alleles *0101, 
*0102, *0401, *0404, *0405, * 
0408, *1001, *1402 
Shared epitope that 
influences antigen 
binding 
Susceptibility , 
risk of erosions  
van der Helm-van 
Mil et al. 2005  
TNF-308GA SNP Increased TNF 
production 
 
Susceptibility , 
disease severity  
Wilson et al. 1997, 
Louis et al. 1998, 
Cvetkovic et al. 2002 
PAD4 (peptidylarginine  
deiminase) SNPs 
Increased 
citrullination 
Susceptibility  
(controversial 
results from  
different 
populations) 
van der Helm-van 
Mil et al. 2005 
PTPN22  (hematopoietic 
protein tyrosine 
phosphatase) SNPs 
Aberrant T cell 
activation 
Susceptibility  Oliver et al. 2006 
SLC22A4 (cation 
transporter) and 
RUNX1 (hematopoietic 
transcription factor) 
SNPs 
Cumulative effect on  
disrupting 
transcription 
Susceptibility  van der Helm-van 
Mil et al. 2005 
ICAM-1, VEGF (vascular 
endothelial 
growth factor) and IL-1RA 
(receptor 
antagonist) SNPs 
Inflammatory 
changes 
Susceptibility  
(non-replicated 
results) 
van der Helm-van 
Mil et al. 2005 
IL-1, IL-2, IL-4 and IL-6 
SNPs 
Inflammatory 
changes 
Disease severity  Oliver et al. 2006 
IL-10 microsatellite 
haplotypes 
(Anti-) inflammatory 
changes 
Disease severity , 
association only in 
females 
van der Helm-van 
Mil et al. 2005 
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MHC class II genes are the most powerful genetic contributors to RA 
recognised so far, covering at least 30% of the total genetic effect. Complexes 
of MHC class II proteins and peptides that are derived from endocytosed or 
phagocytosed antigens are recognised by CD4+ T cells on the surface of 
antigen-presenting cells, i.e. dendritic cells, macrophages and B cells. There is 
no need to express MHC class II molecules on more cell types, because 
activated CD4+ T cells produce cytokines, which amplify the response by 
activating a wide range of cells (Parkin and Cohen 2001, Chaplin 2003). 
The HLA-DRB1 alleles *0101, *0102, *0401, *0404, *0405, *0408, *1001 and 
*1402 encode shared epitope (SE), i.e. a conserved amino acid sequence 
(QKRAA, QRRAA or RRRAA) at a position that contributes to the peptide-
presenting site. Alleles encoding SE are associated with higher susceptibility 
and severity of RA. HLA-DRB1 haplotypes that encode the sequence DERAA 
instead of the shared epitope may protect from RA (van der Helm-van Mil et 
al. 2005).  
Within the HLA region, another potential candidate for RA is TNF -
308GA. In several populations, the -308A allele is more common in healthy 
individuals than in RA patients, but it is also associated with a more severe 
form of RA (Cvetkovic et al. 2002). This may reflect the different need of TNF 
in acute defence and the chronic phase of the disease. 
Female hormonal environment is likely to play a role in the 
pathogenesis, evidenced by the higher RA incidence in women and the pro-
inflammatory effects of estrogens, the receptors of which are expressed on 
synovial macrophages (Kinne et al. 2000). Also, the onset of RA is reduced 
during pregnancy, and increased again postpartum particularly among 
breastfeeders, which may be explained by increased secretion of the pro-
inflammatory hormone prolactin. The use of oral contraceptives also seems to 
protect from RA, possibly by postponing pregnancy (Oliver and Silman 2006). 
Interactions between genetic and environmental factors 
Recently, a large Swedish case-control study revealed for the first time 
gene-environment interactions that operate in the etiology of RA. Smokers 
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carrying two copies of SE had a 21-fold risk of RA when compared to non-
smokers without susceptibility alleles. Long-term exposure to cigarette smoke 
may induce mechanisms that accelerate deimination of arginine to citrulline 
in autoantigens present in the lungs, possibly by up-regulation of PAD 
activity in macrophages. As citrullination increases the binding of peptides to 
SE-containing HLA-DR, the subsequent immune response may be induced in 
individuals carrying SE (Klareskog et al. 2006).  
Innate immune responses 
The severity of RA correlates with the abundance and activity of 
synovial macrophages, which produce large amounts of inflammatory 
cytokines, chemoattractants and proteases at the site of tissue destruction. In 
active RA, an altered cytokine or growth factor milieu may be built up in the 
circulation, leading to rapid generation of CD14 and HLA-DR positive 
myelomonocytic cells in the bone marrow and systemic monocyte activation 
(Kinne et al. 2000). 
Paracrine, autocrine and cellular interactions between synovial 
fibroblasts and macrophages induce cartilage destruction, in which the most 
prominent mediators are IL-1 and TNF (Kinne et al. 2000). They stimulate the 
production of matrix-degrading enzymes (such as MMPs) in fibroblasts. 
Cellular hyperplasia in rheumatic joints partly results from prevention of 
apoptosis as the expression of Bcl family members and soluble Fas ligand is 
increased in fibroblasts (Müller-Ladner et al. 2005). Also, pannus formation 
might be driven by penetration of synoviocytes that produce high amounts of 
MMPs (Lee and Weinblatt 2001). 
The synovial endothelial cells are an active target for cytokines and 
mitogens, which crucially contributes to the expansion of synovial tissue and 
the subsequent increased need for blood vessels. Hypoxia induces the 
production of angiogenic VEGF in the synovial membrane, and pannus is 
highly vascularised (Paleolog 2002). 
Of the other cell types, neutrophils have the greatest capacity to cause 
joint damage, and they are abundantly present in synovial fluid and at the site 
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of early erosions, pannus-cartilage junction (Witko-Sarsat et al. 2000). 
Synovial DCs may constantly receive non-specific stimulation (e.g. from 
minor trauma) in the rheumatoid synovium and migrate to the regional 
lymph nodes (Arend 2001). 
Because only a few protective mechanisms operate in the joints, 
imbalance of any of the regulatory systems may shift the balance between 
matrix production and degradation in the direction of RA chronicity. For 
instance, the ratio of IL-1 and its physiological inhibitor IL-1RA is elevated in 
RA (Kinne et al. 2000). 
The innate receptors TLR4 and TLR2 may mediate RA-associated 
signals. Endogenous TLR4 ligands are abundant in inflamed joints, and an 
association between RA susceptibility and the TLR4 Asp299Gly variant has 
been suggested. Due to the heterodimerisation of TLR2 with either TLR1 or 
TLR6, TLR2 ligands are a diverse group, including native and modified 
bacterial lipoproteins, peptidoglycan and endogenous HSPs. Increased 
numbers of CD16+ monocytes that produce high amounts of pro-inflammatory 
cytokines in response to TLR2 agonists have been detected in peripheral blood 
of RA patients (Brentano et al. 2005).  
Treatment and prognosis  
In early RA, the therapeutic strategies are aimed at obtaining 
remission and preventing joint destruction as soon as possible. These goals 
can be reached with conventional DMARDs or new biological agents. Effective 
early treatment is essential as the majority of the damages can occur within 
the first five years (Morel and Combe 2005). The adoption of standardised and 
validated clinical outcome measures (e.g. the disease activity score DAS in 
Europe) that inform about inflammation, function and quality of life, have 
greatly improved the assessment of treatment. These measures are combined 
with radiological scores (e.g. Larsen score) that assess the severity of erosions 
and joint-space narrowing (Lee and Weinblatt 2001). Physical or occupational 
therapy and patient education accompany the drug therapy (O’Dell 2004). 
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To date, the most common DMARDs are methotrexate (MTX) and 
sulphasalazine. MTX is a folic acid antagonist, which prevents purine and 
pyrimidine synthesis and thereby cell proliferation as high doses (in cancer 
chemotherapy). In the treatment of RA, much lower MTX doses are used that 
prevent the synthesis of tetrahydrofolate. The most common adverse effects of 
MTX include mouth ulcers, nausea and dizziness. The precise mechanism of 
sulphasalazine action is not known. However, it reduces the production of RF 
and TNF, and down-regulates lymphocytes and neutrophils. Sulphasalazine 
may cause intestinal problems and nausea. Other widely used DMARDs 
include hydroxychloroquine, leflunomide, penicillamine, cyclosporine A, 
azathioprine, and gold compounds (Möttönen et al. 2002, O’Dell 2004). 
The treatment strategies include the use of one DMARD, a 
combination of DMARDs or a biological agent. The patients with poor 
prognosis would greatly benefit from the biologicals. However, these drugs 
are expensive and may predispose to serious infections, and patients who do 
not develop significant joint damage do not require them (Morel and Combe 
2005). Anti-inflammatory glucocorticoids are also used (O’Dell 2004). 
The most promising biologicals are TNF inhibitors etanercept, 
infliximab and adalimumab (Nash and Florin 2005) (Table 16). The usefulness 
of TNF as a target is evidenced by several research lines. First, neutralisation 
of TNF suppresses collagen-induced arthritis and reduces inflammation in 
immunodeficient arthritis. Furthermore, deregulated TNF expression causes 
development of chronic arthritis, and TNF levels in the synovial fluid 
Table 16. Licensed tumour necrosis factor (TNF) inhibitors. 
 
 Etarnecept Infliximab Adalimumab 
Type Soluble TNF receptor TNF antibody TNF antibody 
Construct 
 
Recombinant  human 
fusion protein 
Chimeric human-mouse 
monoclonal antibody 
Human monoclonal 
antibody 
Use In monotherapy or 
with methotrexate 
With methotrexate In monotherapy or 
with methotrexate 
 
From Nash and Florin 2005. 
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correlate with the degree of bone erosions (Kinne et al. 2000). 
70% of RA patients develop radiological erosions. Factors predicting 
worse radiological outcome include the SE alleles, high levels of RF and 
ACPAs, early erosions and radiological score at disease onset. Close to 50% of 
the patients are unable to work after 10 years of disease (Morel and Combe 
2005). The predicted lifespan of RA patients is shortened by 15-20%, and the 
increased mortality is often caused by infections and renal disease associated 
with a severe RA. The gastrointestinal problems and hematopoietic 
malignancies leading to death may be treatment-related (Myllykangas-
Luosujärvi et al. 1995). The risk of cardiovascular diseases (with subsequent 
excess mortality) is also increased among RA patients, maybe due to the 
inflammatory phases of the pathologic cardiovascular events (O’Dell 2004). 
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AIMS OF THE STUDY 
The aim of the study was to examine the innate immune system in 
inflammatory rheumatic diseases. The specific aims were to study 
 
1. Innate immune function of subjects with a history of ReA focusing on 
a) monocyte TNF production capacity (Study I) 
b) neutrophil activation using cellular markers CD11b, CD14 and CD16 
(Study II) 
 
2. The prognostic value of innate immune gene alleles: 
a) CD14 -159 and TNF promoter polymorphisms in acute arthritis (Study 
III) 
b) TLR4 +896 polymorphism in early RA (Study IV) 
 
3. Peripheral blood mononuclear VEGF production in association with the 
activation of the innate immune system (Study V) 
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EXPERIMENTAL PROCEDURES 
MATERIALS 
SUBJECTS 
All subjects in studies I-V were native Finns (Table 17). Study V 
comprised healthy subjects. The study protocols were approved by local ethics 
committees (the FIN-RACo protocol also by national health authorities), and 
the subjects gave their informed consent to participate.  
Studies I and II 
Fifteen HLA-B27 positive subjects who had had Yersinia-triggered 
reactive arthritis (Leirisalo et al. 1982) with complete recovery (Leirisalo-Repo 
et al. 1996a) were recruited (Table 17). Fifteen HLA-B27 positive and 15 HLA-
B27 negative healthy laboratory employees served as reference subjects. None 
of the subjects had anti-inflammatory medication or signs of infection at the 
time of donation or during the preceding week. Neither did they have 
subclinical systemic inflammation, verified by a high sensitivity CRP assay.  
Table 17. Characteristics of the subjects in clinical studies (I-IV). 
 
Study n Women/
men 
Age, 
years* 
Early diagnosis Follow-up 
time, years* 
Outcome 
I, II 45 10/5 57 (39-71) ReA 18 (15-25) Recovery 
  10/5 47 (32-64) Healthy (HLA-B27+) - - 
  10/5 53 (43-58) Healthy (HLA-B27-) - - 
III 141 77/64 49 (30-80) ReA, n=93 
Other SpA, n=13 
RA, n=14 
Other inflammatory 
arthritis, n=21 
17 (10-38) Asymptomatic, n=92 
Chronic SpA, n=30 
AS, n=19 
Other SpA, n=11 
Chronic RA, n=11 
Other autoimmune 
disease, n=8 
IV 169 105/64 47 (20-65) RA 0.5 Remission, n=77 
Nonremission, n=92 
 
* Expressed as median (range). n, number of patients; ReA, reactive arthritis; SpA, spondylo-
arthropathy; RA, rheumatoid arthritis; AS, ankylosing spondylitis. 
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Study III 
141 subjects were included who had been diagnosed with spondylo-
arthropathy, rheumatoid arthritis or acute inflammatory arthritis of diverse 
causes (Leirisalo et al. 1982, Valtonen et al. 1985) and re-examined for disease 
outcome (Leirisalo-Repo et al. 1996a, Leirisalo-Repo et al. 1996b) (Table 17). The 
most common early diagnosis was ReA, triggered by Yersinia in 46, 
Chlamydia in 27, Salmonella in 1, Shigella in 1 and an unknown microbe in 18 
patients. 
Study IV 
The patients had been diagnosed with early rheumatoid arthritis and 
participated in the FIN-RACo (FINnish Rheumatoid Arthritis Combination 
therapy) trial (Möttönen et al. 2002). FIN-RACo was a randomised, nation-wide 
multi-center study in which the efficacy and tolerability of a single DMARD 
therapy (sulphasalazine with or without the corticosteroid prednisolone) were 
compared with those of a combination DMARD therapy (sulphasalazine, 
methotrexate, hydroxychloroquine and prednisolone) in active early 
Table 18. Inclusion and exclusion criteria for the FINnish Rheumatoid Arthritis 
Combination therapy (FIN-RACo)  trial. 
 
Inclusion criteria 
Fulfilment of the classification criteria for rheumatoid arthritis by the American 
Rheumatism Association (Arnett et al. 1988) 
Age between 18 and 65 years 
Duration of symptoms < 2 years 
Active disease with three or more swollen joints, and at least three of the following: 
   Erythrocyte sedimentation rate  28mm/h 
   C-reactive protein > 19 mg/l 
   Morning stiffness  29 minutes 
   Number of swollen joints > 5 
   Number of tender joints > 10 
Exclusion criteria 
Previous DMARD usage  
Glucocorticoid therapy within two weeks 
Serious comorbidity 
History of cancer 
Pregnancy or absence of reliable contraception among women at fertile age 
 
DMARD; disease- modifying antirheumatic drug. 
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rheumatoid arthritis (Table 18). Availability of an applicable blood sample 
reduced the number of the 195 FIN-RACo participants to 169 (87 receiving 
single and 82 combination DMARD therapy) in the present study. 
BLOOD SAMPLES 
Studies I and II 
Venous blood samples of 3 ml were collected into Falcon tubes (Becton 
Dickinson, Lincoln Park, New Jersey, USA) containing pyrogen-free heparin 
(Lövens, Ballerup, Denmark) 10 IU/ml blood and placed in an ice-water bath. 
Aliquots were taken for the whole blood culture assay and for flow cytometry, 
which was performed within ten hours of blood sampling. In study I, an 
additional venous blood sample of 7 ml was collected into an EDTA(K3) tube 
(Vacutainer No 367657, Becton Dickinson), aliquoted into Cryo tubes (Greiner 
GmbH, Solingen, Germany) and stored at –70C until the nucleic acid analysis 
was done within four months.  
Study III 
In the studies on the outcome of early arthritis (Leirisalo-Repo et al. 
1996a, Leirisalo-Repo et al. 1996b), a 10-ml sample of venous blood had been 
collected from each patient into a citrate anticoagulant tube and stored at -
18C. Nucleic acid analysis for the present study was done five years later. 
Study IV 
Venous blood samples obtained during the FIN-RACo trial were stored 
at -20C and used for nucleic acid analyses in this study ten years later. 
Study V 
100-ml venous blood samples were collected from 7 healthy subjects, 
anticoagulated by EDTA and diluted with an equal volume 0f 0.9% NaCl. 
Peripheral blood mononuclear cells (PBMNCs) were isolated using Ficoll-
Pague (Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation, 
washed once with PBS containing 10% heat-inactivated fetal bovine serum 
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(Life Technologies, Rockville, Maryland, USA), twice with sterile Dulbecco’s 
modified Eagle’s medium (DMEM, from Life Technologies) and resuspended 
in DMEM. The cells were identified and counted by a Technicon H2 
differential cell counter (Bayer AG, Leverkusen, Germany). The PBMNCs 
were used immediately in serum-free cultures. 
METHODS 
LABORATORY 
Cultures  
Whole blood (Studies I and II) 
 Escherichia coli O111:B4 LPS, phorbol 12-myristate 13-acetate (PMA) 
and Ca2+ ionophore A23187 (all from Sigma, St. Louis, MO, USA) were stored 
at -20C as stock solutions (400 g LPS/ml Dulbecco’s phosphate buffered 
saline (PBS) from Life Technologies Ltd., Paisley, UK; PMA and Ca2+ 
ionophore A23187 both at 5 mM in 99.5% ethanol). LPS was used for receptor-
mediated, and PMA and A23187 for non-specific stimulation of leukocytes.  
100-l aliquots of heparinised blood were added into polypropylene 
tubes (No 352063, Becton Dickinson) or cell culture wells (No 3515, Corning 
Inc., Corning, New York, USA) pre-supplemented with: 1) 800 l of RPMI 1640 
medium (Life Technologies) and 100 l of LPS (finally at 1 g/ml) or 2) 900 l 
RPMI and 1 l of PMA and 1 l of A23187 (both finally at 5 M) or 3) 900 l of 
RPMI 1640 alone. Two sets of cultures were prepared for both 2-hour and 4-
hour incubations, one in test tubes and one in cell culture wells, and incubat-
ed at 37C in 5% CO2. Polypropylene tubes and cell culture wells were used in 
the incubations in order to mimic the non-adherent conditions in the circula-
tion and the adherent conditions on the endothelium at the inflamed site, 
respectively. The culture supernatants were snap-frozen and stored at -70C. 
TNF levels were determined within two months. The cell pellet was suspended 
in 50 l of ice-cold sterile AB serum (Finnish Red Cross Blood Transfusion 
Service, Helsinki, Finland) and used for flow cytometry.  
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Serum-free (Study V) 
The freshly isolated PBMNCs transferred onto multiwell plates were 
incubated in 500 l of DMEM supplemented with 5 mg/ml bovine serum 
albumin (Sigma, St. Louis, Missouri, USA), 50 g/ml gentamicin (Life 
Technologies) and various concentrations of endotoxin from S. typhimurium 
(Sigma) and/or recombinant human interferon-2b (PeproTech, London, UK) 
at 37°C in 5% CO2 for 24 h. The protein synthesis was blocked using 1 mM 
cycloheximide (Sigma). 
Nucleic acid analyses  
CD14 and TNF promoter SNPs (Studies I and III) 
DNA was isolated using QIAamp DNA Blood Midi Kit (QIAGEN, 
Hilden, Germany). Fragments containing the target single nucleotide poly-
morphisms (SNPs) were amplified by multiplex polymerase chain reaction 
(PCR). Thereby, 5 l of sample DNA (5 ng/l) were added to 20-l mixtures on a 
96-well PCR plate (Thermo-Fast 96, ABGene, Epsom, Surrey, United Kingdom) 
that contained 12.5 pmols of each of the multiplex PCR primers (Table 19), 
dNTPs at 200 M (Pharmacia Biotech, Uppsala, Sweden) and 0.5 U of 
AmpliTaq Gold polymerase (Perkin Elmer, Boston, Massachusetts, USA) in 
DyNAzyme buffer (Finnzymes, Espoo, Finland). After initial denaturation (at 
96C for 7 min), 35 amplification cycles (at 96C for 1 min, 60C for 1 min, and 
72C for 2 min) were run in a thermal cycler (MJ Research DNA Engine 200). 
Unreacted dNTPs and primers were removed by treating the amplification 
products with 5 l of SAP-EXO mix (1 U of shrimp alkaline phosphatase and 5 
U of exonuclease I, both from USB, Cleveland, Ohio, USA) at 37C for 30 min, 
after which the enzymes were inactivated at 80C for 15 min.   
The PCR products were diluted 1:1 (v/v) in DyNAzyme buffer 
(Finnzymes), divided into 8 aliquots, 5 l each, on new 96 or 384 PCR plates 
(Thermo-Fast 96 or 384). The plates had been prealiquoted with reagents for 
the SNP determination by an automated cycle minisequencing technique. 
(Figure 8, Table 19)  
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Figure 8. Cycle minisequencing procedure. 
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R < 0.1 = homozygous for the polymorphic allele 
0.5 < R < 2.5 = heterozygous for the wild type/polymorphic allele 
R > 10 = homozygous for the wild type allele 
 
(1) 3H-labelled nucleotides, specific activity 69 Ci/mmol for dATP, 53 Ci/mmol for dCTP, 32 
Ci/mmol for dGTP and 96 Ci/mmol for dTTP (Amersham Life Science, Little Chalfont, 
Buckinghamshire, UK); (2) DNA polymerase II (Finnzymes); (3) streptavidin-coated 
ScintiStrips (Wallac, Turku, Finland) containing 0.1% Tween 20 in PBS, 50 mM NaOH for 5 
min; (4) MiniTent buffer (Helsinki University Central Hospital, Helsinki, Finland); (5) beta 
counter (Microbeta, Wallac). 
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TLR4 +896 SNP 
DNA was isolated using QIAamp DNA Blood Mini Kit (QIAGEN). The 
A/G polymorphism at +896 of the TLR4 gene was analysed by an allele-specific 
hybridisation method (TaqMan). Amplification was performed in an ABI 
Prism Sequence Detector 7000 (Applied Biosystems, Foster City, California, 
USA) using 100-well plates. The final volume was 5 μl containing 0.8 μl of DNA 
solution at a concentration of 5 ng/μl, 0.1 μl of each primer (100 pmol/μl, Table 
 Table 19. Primer and probe sequences. 
 
 
 
 Multiplex PCR primers 
For fragment containing CD14 -159 (Studies I and III) 
5’-CCT GGA AAT ATT GCA ATG AAG GAT G-3’ 
5’-CCA GGA GAC ACA GAA CCC TAG ATG C-3’ 
 
 For fragment containing TNF -238, -308, and -376 (Studies I and III) 
5’-CCT CAA GGA CTC AGC TTT CTG AAG-3’  
5’-AAG TTG GGG ACA CAC AAG CAT C-3’ 
 
 For fragment containing TLR4 +896 (Study IV) 
5’-TGA CCA TTG AAG AAT TCC GAT TAG CA-3’ 
5’-ACA CTC ACC AGG GAA AAT GAA GAA-3’ 
 
   
 Cycle minisequencing primers (Studies I and III) 
For CD14 -159 determination 
5’-Biotin-GCA GAA TCC TTC CTG TTA CGG-3’ 
For TNF -238 determination 
5’-Biotin-AGA AGA CCC CCC TCG GAA TC-3’ 
For TNF -308 determination 
5’-Biotin-CAA TAG GTT TTG AGG GGC ATG-3’ 
For TNF -376 determination 
5’-Biotin-GGT CTG TGG TCT TCC TTC TAA-3’ 
 
   
 Allele-specific hybridisation (Study IV) 
Probes for TLR4 +896 determination 
FAM-5’-CCT CGA TGG TAT TAT T-3’ 
VIC-5’-TAC CTC GAT GAT ATT ATT-3’ 
 
   
 RT-PCR primers (Study V) 
For VEGF mRNA determination 
5’-AAGCCATCCTGTGTGCCCCTGATG-3’ 
5’-TCCTTCCTCCT-GCCCGGCTCAC-3’ 
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19), 0.1 μl of each probe (100 pmol/μl) (Table 19), 2.5 μl of TaqMan Universal 
PCR Master Mix (Perkin-Elmer), and 1.3 μl of distilled water. The PCR 
conditions were: initial holding at 50°C for 2 min, denaturation at 95°C for 10 
min, and 40 cycles of denaturation (95°C for 15 s), annealing, and extension in 
one step (60°C for 60 s). Each assay included controls for the wild type and 
mutations. 
Northern blotting (Study V) 
The RNA was extracted from isolated PBMNCs using RNeasy RNA 
extraction kit (QIAGEN), denaturated in loading dye (Ambion, Austin, Texas, 
USA), size-fractioned on a 1% agarose gel by electrophoresis, blotted onto a 
nylon membrane and fixed by UV cross-linking. The VEGF probe, a 549-bp 
fragment of cloned human VEGF121 cDNA, was labeled using BrightStar 
Psoralen-Biotin kit (Ambion). The RNA membranes were hybridised with 0.3 
ng/ml of the probe in ULTRAhyb solution (Ambion) at 60°C overnight. The 
probe was detected using BrightStar BioDetect kit (Ambion), the membranes 
were exposed to autoradiographic films (Hyperfilm ECL, Amersham 
Pharmacia Biotech, Piscataway, New Jersey, USA) and the signals were 
quantified densitometrically by NIH Image software. To normalise the VEGF 
mRNA levels, the blots were hybridised with a 1.1-kb human glyceraldehyde-3-
phosphate mRNA probe (Clontech, Palo Alto, California, USA).   
Isoform-specific RT-PCR (Study V) 
To reveal the expression of mRNAs encoding the four VEGF isoforms, 
primers specific for exons 3 and 8 were used (Table 19). The 50-μl RT-PCR 
reaction contained 1.0 μg of total RNA, the VEGF-specific primer pair, 40 U of 
human RNase inhibitor (Ambion) and components of One-Step RT-PCR kit 
(QIAGEN). 
After a 30-min reverse transcription reaction at 50°C and initial 
denaturation (at 95°C for 15 min), the amplification cycle of denaturation (at 
94°C for 1 min), annealing (lowering the temperature gradually from 72°C to 
67°C during the first five cycles) and extension (at 72°C for 1 min) was run 35 
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times. The PCR products were electrophoresed on a 2% agarose gel, stained 
with 0.5% ethidium bromide and visualised under UV light. A 100-bp DNA 
ladder (New England BioLabs, Beverly, Massachusetts, USA) was used as a 
molecular weight marker. 
Immunoassays 
TNF (Study I) 
The cell culture supernatants were thawed and diluted 1:5 in TNF 
Sample Diluent (Diagnostic Products, Los Angeles, CA, USA). The TNF levels 
were measured by Immulite, a chemiluminescent immunoassay analyser 
(Diagnostic Products). The detection limit was 4 pg/ml. The intra-assay 
variation was 9% and the interassay variation 12%. The concentrations were 
corrected for dilution and background.  
VEGF (Study V) 
The serum-free culture medium was collected and centrifuged (250 g) 
to remove debris. The concentrations of VEGF polypeptides were determined 
using Quantikine Human VEGF Immunoassay, a quantitative sandwich 
enzyme technique (R&D Systems, Minneapolis, Minnesota, USA).  
Immunostaining (Studies I and II) 
Two 25-l aliquots of both heparinised blood and cell pellet suspended 
in AB serum were placed in polystyrene tubes (No 2058, Becton Dickinson) 
and stained with pretitrated amounts of FITC-anti-CD11b (mouse mAb IgG1, 
clone BEAR 1 from Immunotech, Marseille, France) and either RPE-anti-CD14 
(mAb IgG2a, clone TüK4 from DAKO A/S, Glostrup, Denmark) and PC5-anti-
CD16 (mAb IgG1, clone 3G8 from Immunotech) or irrelevant mouse mAbs PC5-
IgG1 (Clone 679.1Mc7 from Immunotech) and RPE-IgG2a (clone DAK-GO5 from 
DAKO A/S). 
After staining for 20 min in dark at 0°C, erythrocytes were lysed by 
1:10 diluted ice-cold FACS lysing solution (Becton Dickinson, San Jose, CA, 
USA), cells were separated by centrifugation (1400 rpm), the supernatant was 
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removed and the cells were resuspended in 2 ml of FACS lysing solution at 
room temperature. The leukocytes were pelleted as before, resuspended in 1% 
formalin at 0°C and kept in dark on ice. Flow cytometric data acquisition was 
performed within 4 hours.   
Flow cytometry (Studies I and II) 
A FACSort flow cytometer (Becton Dickinson) and CellQuest software 
were used for data acquisition. QuantiBRITE PE bead standards (Becton 
Dickinson) were run weekly. The data were analysed using QuantiCalc 
software (Verity Software House, Topsham, ME, USA). First, CD11b-positive 
events (monocytes, neutrophils, some lymphocyte populations) were 
delineated in side scatter/CD11b (FITC intensity) dot plot by the region R1 
(Figure 9A). Second, side scatter/forward scatter dot plot was created from R1, 
and R2 was set to delineate the monocyte population for Study I (Figure 9B). 
At least 1×103 monocytes i.e. events co-locating in R1 and R2 were collected. 
For Study II, neutrophil CD11b levels, expressed as relative 
fluorescence units (RFUs), were obtained by plotting CD11b against CD16 (PC5 
intensity) of the collected events. Monocyte contamination was excluded by 
electronic gating based on the high CD16 expression on neutrophiles 
compared to that of monocytes. According to the manufacturer, the number of 
PE-linked anti-CD14 molecules equals to each cell’s CD14 antibody-binding 
capacity (ABC). ABC medians for monocytes (Study I) and neutrophils (Study 
II) were determined by creating a fluorescence intensity plot CD14 (PE) vs. 
CD16 (PC5) (Figure 9C). CD16 levels were given as RFUs (Study II).  
DATA ANALYSIS 
Study I  
The differences in TNF levels obtained in different culture conditions 
were compared using Wilcoxon signed ranks test. Differences between the 
three subject groups were evaluated by Kruskal-Wallis test, and in post hoc 
analysis by Mann-Whitney U test. When testing for linear trend in the subject 
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groups having 0, 1 or 2 risk factors, Jonckheere-Terpstra test was used. The 
CD14 -159 minor allele prevalences were calculated using Fisher’s exact test.  
Study II  
The differences in CD11b expression in different culture conditions 
were compared by Friedman test, or in case of two different conditions only, 
by Wilcoxon signed ranks test. The three subject groups were compared using 
Jonckheere-Terpstra test.  
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Figure 9. Analysis of CD14 and CD16 surface markers on CD11b positive monocytes. 
Peripheral blood leukocytes were triple-labelled with fluorescent mAbs. A, CD11b positive 
cells were delineated by R1; B, monocytes were delineated by R2; C, dot plot was developed 
from monocytes (cells co-locating in R1 and R2), the median CD14 expression and the 
proportion of CD14+CD16+ monocytes (R3) were calculated. ABC, antibody-binding capacity; 
RFU, relative fluorescence unit. 
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Study III  
Differences in TNF -308G/A and CD14 -159C/T allele frequencies 
between the patient groups were calculated by -square test. 
Study IV 
The treatment response in the TLR4 +896AA and AG/GG groups, 
presented by DAS28 values, was evaluated using generalising estimating 
equation models with exchangeable correlation structure. DAS28 remission 
was estimated by multivariate logistic regression with bootstrap estimate of 
variance.  
Study V 
Wilcoxon signed ranks test was used when comparing the secretion of 
VEGF in different culture conditions. 
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RESULTS AND DISCUSSION 
INFLAMMATORY PHENOTYPE 
PHAGOCYTE RESPONSIVENESS 
TNF secretion by whole blood monocytes of subjects with previous ReA 
(Study I) 
In adherent cultures, whole blood monocytes from HLA-B27 positive 
healthy subjects with previous Yersinia arthritis (B27+ReA+) released more 
TNF in response to non-specific stimulation of the protein kinase C pathway 
(stimulated by PMA and Ca2+ ionophore) than those of HLA-B27 positive 
reference subjects (B27+ReA-) did. The difference was significant both at 2 and 
4 hours of incubation (Study I: Figure 2A and B) and not evident in non-
adherent cultures. Further, when the PMA- and Ca2+ ionophore -stimulated 
adherent and non-adherent conditions were compared, the 2-hour TNF levels 
were significantly higher in the former in all subject groups (B27+ReA+, 
B27+ReA- and B27-ReA-), but the difference was significantly higher in 
B27+ReA+ group than in the reference groups. On the other hand, in non-
adherent cultures the induction of TNF production was even slower (i.e. the 
kinetic ratio TNF at 4 hours / TNF at 2 hours was higher) in the B27+ReA+ 
samples than in those of the reference subjects (with the absolute TNF levels 
being comparable between the groups) (Study I: Figure 2C). Hence, the 
elevated TNF levels in the B27+ReA+ group appeared to be associated with 
adherence. 
These results may indicate that monocytes that have the capacity to 
produce high amounts of TNF in response to non-specific stimulation on 
adhering to the synovial vessels could promote acute joint inflammation. It is 
noteworthy that low TNF secretion by blood mononuclear cells in response to 
phytohaemagglutinin has been reported to correlate with chronicity of 
arthritis (Westendorp et al. 1995). Hence, it is possible that a vigorous rapid 
TNF response of adhered phagocytes provokes clinical joint inflammation 
and, on the other hand, helps to overcome the disease more quickly. Also, 
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considering that circulating monocytes continuously adhere to the 
endothelium and extravasate to become tissue macrophages, increased 
response to non-specific stimuli thereby may contribute to the initiation of 
inflammation. Consistent with the significance of adhesion in our results, the 
proportion of circulating CD14+CD16+ monocytes, which have high capacity 
of TNF production, was not elevated in the samples of the B27+ReA+ subjects. 
The molecular basis of the observations may include some 
aberration(s) in adhesion-associated intracellular signalling. Interestingly, 
signalling through the cell-surface integrin CD11b/CD18, the main mediator of 
monocyte adhesion to the endothelium and cell culture well surfaces (Wallis et 
al. 1985, Springer and Anderson 1986), is known to enhance TNF production 
(Dackiw et al. 1996) and monocyte survival (Nakamura et al. 1998).  
TNF secretion by whole blood monocytes of healthy HLA-B27 negative 
reference subjects (Study I) 
When the basic guidelines of TNF production kinetics were evaluated 
by excluding the effect of previous ReA and the SpA susceptibility gene HLA-
B27, significant differences between adherent and non-adherent conditions 
appeared on LPS stimulation (but not on PMA- and Ca2+ ionophore-
stimulation) (Study I: Figure 1). The TNF levels of the adherent samples of the 
HLA-B27 negative group remained stable after two hours of culture (Study I: 
Figure 1A), whereas in non-adherent conditions they increased thereafter 
(Study I: Figure 1B). This may suggest that in the presence of bacterial LPS, 
adhesion-mediated intracellular signalling for TNF production turns 
repressive as the response advances. If exerted in vivo, the results could mean 
that the more restrained TNF production of adhered phagocytes may be 
biologically meaningful and aimed at protecting endothelial cells from undue 
exposure to TNF. 
CD11b expression by whole blood neutrophils of subjects with previous 
ReA (Study II) 
When stimulated by LPS (as 100 pg/ml, 10 ng/ml or 1 g/ml) in non-
adherent conditions, or without LPS supplement in adherent conditions, 
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neutrophils of the B27+ReA+ subjects showed significantly higher surface 
expression of the activation marker CD11b than those of the B27-ReA- subjects 
did (Study II: Figure 1). In vivo, the sources of LPS are ubiquitous, and LPS 
can occur in healthy subjects as high as 1 ng/ml in the portal venous blood. 
Minor trauma in the intestine, for example, may allow the leakage of LPS 
from the gut into the circulation. Bacterial antigens including LPS may also 
persist in the peripheral blood cells of Yersinia patients who develop ReA 
(Granfors et al. 1998).  
The differences in CD11b expression might derive from aberrations in 
LPS signalling pathways, e.g. functional TLR4 polymorphisms, since TLR4-
mediated signalling leads to up-regulation of CD11b on neutrophils (Zhou et al. 
2005), or at the level of CD11b/CD18. Also, because LPS-stimulated TNF 
production did not differ between the subject groups, signalling triggered by 
TNF is not likely to explain the differences in CD11b levels. Priming, defined 
by enhanced oxygen radical production, has been detected in neutrophils of 
subjects with previous Yersinia arthritis (Ristola 1990), and may also be 
associated with the elevated CD11b levels. Constitutive CD11b expression, the 
levels of CD14 and CD16, or CRP levels did not differ between the subject 
groups, excluding the possibility that an ongoing cryptic infection was the 
reason for our finding.  
The results suggest that neutrophils of the B27+ReA+ subjects can be 
very responsive when encountering circulating LPS or an adherent surface, 
which could be associated with the development of ReA. The response may be 
highly meaningful because neutrophils are abundant, comprising 70% of 
peripheral blood leukocytes in adults.  
Altogether, the molecular mechanisms of the observed adhesion-
associated phenomena in TNF production and CD11b expression are subject to 
our further studies.  
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ANGIOGENESIS AND TISSUE EDEMA 
VEGF production by PBMNCs of healthy subjects (Study V) 
VEGF acts as an angiogenesis-promoting mitogen for endothelial cells 
and strongly increases vascular permeability. It has a dual role both in 
healing of tissue damage and pathophysiology, both of which include 
angiogenesis. Our results showed that LPS as 20 pg/ml-2 ng/ml, which cover 
physiological LPS levels, increase de novo VEGF production of PBMNCs in a 
dose-dependent manner (Study V: Figure 2). The expression pattern of the 
four VEGF mRNA sizes of the stimulated cells was comparable to that of non-
stimulated cells.  IFN- a cytokine with immunoregulatory capabilities, 
inhibited both non-stimulated (Study V: Figure 4) and LPS-stimulated (Study 
V: Figure 5) VEGF production of PBMNCs. 
Tissue edema attributed to increased vascular permeability is 
associated to local and systemic inflammation and various malignancies. 
Also, angiogenesis involving VEGF occurs early in the chronic stage of 
rheumatoid arthritis as the synovial hyperplasia leads to pannus formation. 
The level of joint damage correlates with the level of serum VEGF (Paleolog 
2002). Our results suggest that the release of VEGF from circulating and 
tissue-migrating LPS-activated PBMNCs is a mechanism that could promote 
edema and progression to the chronic stage of RA. As PBMNCs are long-living 
cells, they may provide a long-lasting source of VEGF.  
IFN-is likely to modulate and oppose the effects of early pro-
inflammatory cytokines. It may reduce the TNF response to LPS thus 
preventing damage caused by innate immunity, and systemic consequences 
(Amadori 2007). In the joints, the protective effect of IFN- may be partly 
implemented by up-regulating functional TNF and IL-1 antagonists (sTNFR 
and IL-1RA) (Wong et al. 2003). Possibly, our finding that IFN- inhibits non-
stimulated and LPS-induced VEGF synthesis may represent another means of 
preventing (joint) damage that is attributed to innate responses. It may partly 
explain the clinical efficacy of IFN-e.g. decrease of joint inflammation in RA 
(Shiozawa et al. 1992) and regression of cancer (Lindner et al. 1997). 
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Despite of the accumulating data of the predominantly anti-
inflammatory effects of IFN-, this cytokine has also been reported to induce 
arthritic manifestations (Ioannou and Isenberg 2000). It is becoming clear that 
the effects of IFN- are dependent of its concentration, target tissue, way of 
administration and the progression of the disease (Brassard et al. 2003, 
Amadori 2007). Hence, the dependence must be studied in detail in order to 
evaluate the overall clinical usefulness of IFN-in the treatment of 
inflammatory conditions such as rheumatoid arthritis (Wong et al. 2003).  
GENETIC FACTORS 
CD14-159C/T, TNF-308G/A AND PATIENTS WITH ARTHRITIS 
TNF production (Study I) 
The LPS-stimulated TNF production of whole blood monocytes was 
CD14-159T allele dose-dependent (Study I: Figure 3), which is in agreement 
with a previous study (Eng et al. 2004). The frequency of the T allele in our 
study was 40%, which is also consistent with other studies, e.g. those 
involving ethnic groups in India (Sharma et al. 2004) and Germany (de la 
Fontaine et al. 2005).  
In the past when antimicrobial therapies were not available, carriage 
of alleles that promote high TNF production on encountering pathogens may 
have provided the host with a significant selective advantage. Since then, the 
environment and hygiene conditions have changed especially in the 
developed countries, giving different kind of stimulation to the immune 
system (Aguillón et al. 2006). The alleles associated with high TNF production 
are possibly advantageous in some of the new challenges. Allergies, for 
example, may represent diseases against which the CD14 -159T allele is 
protective (Sharma et al. 2004). 
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Susceptibility 
Acute disease (Studies I and III) 
The frequency of the minor alleles CD14 -159T (Studies I and III) and 
TNF -308A (Study III: Table II) did not differ between the acute arthritis and 
reference groups, suggesting that these SNPs do not affect the susceptibility of 
acute arthritis. Regarding our result of the PMA- and Ca2+ ionophore-induced 
TNF production capacity of the B27+ReA+ monocytes and the fact that CD14 
belongs to the LPS receptor complex, the conclusion may be that the monocyte 
response to non-specific stimuli and adherence is more potently associated 
with acute arthritis than the CD14 -159 polymorphism-associated LPS-induced 
increase in TNF production is. 
Chronic disease (Study III) 
All female patients who developed chronic SpA during the follow-up 
time had the CD14 -159T allele and none of them had the TNF -308A allele, a 
phenomenon not seen in male patients (Study III: Table II). The finding is in 
concordance with studies suggesting that female sex hormones as well as the 
absence of TNF -308A may depress effective responses in inflammation: TNF 
production may be decreased by estrogen (Srivastava et al. 1999) and IL-1 
production by estradiol and progesteron (Morishita et al. 1999), whereas TNF -
308A has been associated with high TNF production (Wilson et al. 1997, Louis 
et al. 1998, Abraham and Kroeger 1999) and protection of AS (McGarry et al. 
1999).  
The molecular background of CD14 -159T involvement seems more 
confusing, as this allele has been reported to increase CD14 expression (Le 
Van et al. 2001) and, in this study, to promote TNF production. It is possible 
that increased shedding of mCD14 occurs on prolonged LPS stimulation to 
prevent excessive monocyte activation, since sCD14 facilitates LPS clearance 
(Miyake 2004). Indeed, -159TT homozygotes have been described to have 
increased sCD14 levels (Baldini et al. 1999). It may also be that besides TNF 
production, other responses originating at the LPS receptor complex, e.g. IFN-
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 induction (Pålsson-McDermott and O’Neill 2004), may dictate the 
development of the chronic disease. Finally, -159T has been associated with 
increased risk of chronic inflammatory bowel disease, i.e. Crohn’s disease 
(Klein et al. 2002) and ulcerative colitis (Obana et al. 2002), raising the 
possibility that LPS from the gut may also be involved in the pathogenesis of 
chronic SpA in patients with the T allele. 
Owing to the low number of the females who developed chronic SpA 
(n=6), the finding must only be taken as very preliminary. However, if 
confirmed in larger studies, CD14 -159T and concomitant absence of TNF -
308A may represent a susceptibility profile of developing chronic SpA in 
females.  
EFFECT OF HLA-B27 (STUDIES I AND II) 
HLA-B27 is a well-known risk allele in spondyloarthropathies, 
although its role in the pathogenesis has not been explained yet. In Study I, 
TNF production of adhesion- and LPS-stimulated whole blood samples of the 
B27+ReA+ group was higher than those of the B27-ReA- but not the B27+ReA- 
group. However, the TNF production capacity studied by the strong non-
specific stimulation (as described above), was associated with previous ReA 
but not with the B27 genotype. This suggests that enhanced LPS receptor-
mediated response and B27 positivity are independent but additive factors 
that may operate in the pathogenesis of ReA. This idea is further supported by 
the results from Study II, in which the neutrophil CD11b levels exhibited a 
trend: B27+ReA+ > B27+ReA- > B27-ReA- (Figure 1 in Study II). Recent 
findings suggest that B27 polypeptides are prone to misfold and subsequently 
accumulate in the endoplasmic reticulum (ER), thus launching ER stress 
responses, which in turn can alter cellular homeostasis (Penttinen et al.  2004). 
Thereby, the proteins that receive essential information, like CD11b/CD18, 
may be regulated differently in terms of their synthesis (Zhou et al. 2005) or 
mobilisation to the cell surface in vesicles or granules (Sengelov et al. 1993). 
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TLR4 +896A/G AND PATIENTS WITH EARLY RA  
Treatment response (Study IV) 
It is often difficult to predict if an individual RA patient will respond 
successfully to the chosen treatment strategy. Hence, discovering biochemical 
and genetic markers that significantly affect the treatment response would be 
highly useful. It is known that the maintenance of optimal working capacity 
can be predicted when a satisfying treatment response is achieved during the 
first 6 months of treatment (Puolakka et al. 2005). In our study, of the patients 
with early RA who had been treated with a single DMARD (started with 
sulphasalazine) for 6 months, patients having the TLR4 minor allele +896G 
achieved remission less often (Study IV: Figure 1) and required more intra-
articular corticosteroid injections than patients homozygous for the wild-type 
A allele did. Among patients treated with a combination of DMARDs 
(sulphasalazine, methotrexate and hydroxychloroquine) and prednisolone, 
there was no difference in the treatment response between the genotypes 
studied. Thus, TLR4 +896A/G (causing the amino acid susbstitution 
Asp299Gly in TLR4) may be a good candidate in distinguishing the patients 
who would get advantage from the combination treatment of RA. 
Microbes as well as autoantigens have been suggested to be involved 
in the pathogenesis of RA (Arend 2001, Oliver and Silman 2006). As the 
Asp299Gly change reduces negative charge and possibly disrupts the 
secondary structure of the extracellular domain of TLR4 (Arbour et al. 2000), 
our present findings may be explained by altered interaction of TLR4 with 
LPS, endogenous ligands (such as those released from injured joints) or the 
other components of the LPS receptor complex. This could be an aberration 
that a single DMARD is not able to overcome. It is also possible that the minor 
allele disrupts the transport of TLR4 to the cell surface. Of interest, TLR4 
substitutions have been associated with better resistance to localised LPS-
induced inflammation, but also with greater susceptibility to systemic 
responses (Arbour et al. 2000), such as those occurring in RA. 
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CONCLUSIONS 
Elevated TNF production by monocytes in response to adherent 
conditions or non-specific stimulation (Study I), and increased CD11b 
expression on neutrophils in response to adherent conditions or LPS (Study 
II) may contribute to the inflammatory pathogenesis of reactive arthritis 
(Figure 10). 
CD14 -159T and TNF -308A (Study III) do not affect the susceptibility of 
acute arthritis. -159T increases LPS-stimulated TNF production in an allele 
dose -dependent manner (Study I). The concomitant presence of -159T and 
absence of -308A may predispose to the development of chronic 
spondyloarthropathy in females (Study III). 
TLR4 +896G can impair treatment response to a single DMARD in 
recent-onset rheumatoid arthritis, suggesting that individuals with this allele 
should receive early combination DMARD therapy (Study IV). 
LPS induces VEGF production by peripheral blood mononuclear cells, 
which could be one mechanism causing edema and angiogenesis in 
rheumatoid joints. The ability of IFN- to oppose this effect may contribute to 
the anti-inflammatory potency of IFN- (Study V). 
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Figure 10. Schematic presentation of how innate immune factors could be associated with 
reactive arthritis (ReA). In the present study, HLA-B27 positive subjects with previous ReA 
showed high TNF production by blood monocytes in response to adherent conditions and non-
specific stimulation, and high expression of the activation marker CD11b on blood neutrophils in 
response to adhesion or LPS. TNF is a crucial pro-inflammatory cytokine that e.g. increases the 
expression of adhesion molecules on the endothelium, thus promoting the recruitment of 
circulating leukocytes to inflammatory foci. CD11b is part of the adhesion molecule CD11b/CD18 on 
the phagocyte surface.  
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